Document:

exv10w3

Exhibit
10.3

PUT RIGHTS AGREEMENT

          This
Put Rights Agreement (this “Agreement”), dated as of
December 31, 2009, is
entered into by and among Henry Schein, Inc., a Delaware corporation, or its successor
(“HSI”), Burns Veterinary Supply Inc., a New York corporation (“Burns”) and, solely
for purposes of Sections 2.5(d) and 2.5(e) of this Agreement, Butler Animal
Health Holding Company, LLC, a Delaware limited liability company, or its successor (the
“Company”).

          WHEREAS, as a condition to the consummation of the transactions contemplated by the Omnibus
Agreement (as defined below), the parties have agreed to enter into this Agreement.

          NOW, THEREFORE, in consideration of the promises and of the covenants and agreements
hereinafter set forth and for other good and valuable consideration, the receipt and adequacy of
which are hereby acknowledged, the parties hereby agree as follows:

ARTICLE I

DEFINITIONS

     1.1. Definitions.

          (a) Capitalized terms used but not defined herein shall have the respective meanings given to
such terms in the Operating Agreement (as defined below).

          (b) For the purposes of this Agreement, each of the following terms shall have the following
respective meanings:

               “30-Day True-Up Period” means a 30-day period commencing
on the day that HSI provides notice to Burns that either (a) an Oak Hill Put Closing has occurred and the Oak Hill Put Price has been paid to Oak Hill or  (b) no Oak Hill Put Notice was given during a Put
 Year; provided, however, that a 30-day True-Up Period shall only commence from and after the fifth anniversary of the Closing Date.

               “Agreement” shall have the meaning set forth in the Preamble.

               “Annual Burns Put Limitation Amount” means, (i) for any Pre Divestiture Put Year, the
lesser of (x) the number of BAHHC Common Shares valued (in accordance with Section 2.2) at
an amount equal to the difference between $150,000,000 and any Oak Hill Put Price paid by HSI to
Oak Hill with respect to an Oak Hill Put Notice delivered during such
Pre Divestiture Put Year, and (y) 41,127.14 BAHHC Common Shares, and
(ii) for any Post Divestiture Put Year, 41,127.14 BAHHC Common Shares.
Notwithstanding the foregoing, in no event shall the Annual Burns Put Limitation Amount exceed an amount equal to the difference between $150,000,000 and any Oak Hill Put Price paid by HSI to Oak Hill during the twelve month period immediately prior to any Burns Put Closing.

               “BAHHC Common Shares” means the “Common Shares” or, following an Initial Public
Offering, the “Successor Common Stock” (each as defined in the Operating Agreement), in each case,
as adjusted for any reclassification, recapitalization, distribution, split, combination, exchange
or similar adjustment thereof.

               “Burns” shall have the meaning set forth in the Preamble.

 

 

               “Burns Put Closing” shall have the meaning set forth in Section 2.4(a).

               “Burns Put Closing Date” shall have the meaning set forth in Section 2.4(a).

               “Burns Put Price” means the aggregate amount payable to Burns in connection with the
exercise of a Burns Put Right, calculated by multiplying either (1) the Put Interest
Percentage and the Fair Market Value in the case of Sections 2.2(a) and 2.2(b)(ii)
or (2) the Market Price and the number of BAHHC Common Shares designated as Put Securities in the
case of Section 2.2(b)(i), as applicable; provided, that, in the case of
Section 2.2(a), the Burns Put Price shall equal (w) the amount as provided in clause (1)
above plus (x) the Excess Tax Distribution Adjustment Amount, if it is positive, or
minus (y) the Excess Tax Distribution Adjustment Amount, if it is negative, and
minus (z) the LIFO Tax Adjustment Amount, and on the Put Closing Date (A) Burns shall
transfer to HSI the entitlement with respect to the amounts in clause (x) and (B) HSI shall assume
from Burns the obligations with respect to the amounts in clauses (y) and (z).

               “Burns Put Right” shall have the meaning set forth in Section 2.1(a).

               “Closing Date” shall have the meaning set forth in the Omnibus Agreement.

               “Commission” means the United States Securities and Exchange Commission, or any other
federal agency administering the Securities Act and the Exchange Act at the time.

               “Company” shall have the meaning set forth in the Preamble.

               “Convertible Security” means any capital stock, equity or debt security convertible
into, exchangeable for or representing any rights to subscribe for or acquire any BAHHC Common
Shares. For purposes of clarification, “Convertible Security” shall not include any options.

               “Darby” means the Darby Group Companies, Inc., a New York corporation.

               “Decision Period” shall have the meaning set forth in Section 2.2(a)(ii)(2).

               “Designated Investment Banker” shall have the meaning set forth in Section
2.2(a)(ii)(1).

               “Discount Rate” means
the National Municipal Bond Yields for AAA Rated Tax Exempt General Obligations Bonds as reported by Bloomberg for the nearest period of time remaining with respect to the tax liabilities to the FIFO tax adjustment, which as of November 29, 2009 is 0.66% for the two (2) year bond.

               “Enterprise Value Methodology” means a methodology to be considered by the Designated
Investment Banker in connection with its determination of Fair Market Value, whereby first, the
enterprise value of the Company is calculated by multiplying (i) normalized EBITDA by (ii) an
appropriate multiple as determined by the Designated Investment Banker,
and second, total cash and cash equivalents of the Company and its subsidiaries as of the most

2

 

recent full month-end balance sheet date immediately preceding the applicable Put Notice Date would
be added thereto, and third, from the enterprise value so calculated, the total indebtedness of the
Company and its subsidiaries for borrowed monies as of the most recent full month-end balance sheet
date immediately preceding the applicable Put Notice Date would be subtracted.

               “Excess Tax Distribution Adjustment Amount” means an amount equal to the difference
between (i) the aggregate net amount that would have been received by Burns with respect to the Put
Securities if on the day immediately preceding the Burns Put Closing Date the Company had made a
distribution to its members in the minimum amount sufficient to eliminate the distribution advances
to all members (including accrued amounts in the nature of interest) provided for in Section
6.6(a)(ii) of the Operating Agreement outstanding as of that day (the “First Distribution”)
and then redistributed the amount of distribution advances treated as repaid pursuant to Section
6.6(a)(ii), and (ii) the aggregate amount that would have been received by Burns with respect to
the Put Securities if on the day immediately preceding the Burns Put Closing Date the Company had
made a distribution to its members in the amount of the First Distribution but on that date the
amount of the distribution advances provided for in that Section 6.6(a)(ii) for all members had
been zero (in both cases not taking account of any adjustments relating to tax liabilities
resulting from the change by the Company from the LIFO to the FIFO inventory accounting method).
To the extent the amount determined under clause (i) of the immediately preceding sentence exceeds
the amount determined under clause (ii) of that sentence the Excess Tax Distribution Adjustment
Amount shall be considered “positive”; to the extent the amount determined under that clause (ii)
exceeds the amount determined under that clause (i) the Excess Tax Distribution Adjustment Amount
shall be considered “negative”.
Attached hereto as Exhibit A is an example of the Excess Tax Distribution Adjustment Amount calculation set forth above.

               “Fair Market Value” means the fair market value of 100% of the equity interests of the
Company, calculated as of the relevant Put Notice Date (except as specifically provided in the
definition of Enterprise Value Methodology), determined pursuant to Section 2.2(a) or
Section 2.2(b)(ii), as applicable.

               “Final Determination” shall have the meaning set forth in Section
2.2(a)(ii)(1).

               “Final Notice” shall have the meaning set forth in Section 2.2(a)(ii)(2).

               “Governmental Authority” shall mean any government or any agency, bureau, board,
commission, court, department, official, political subdivision, tribunal or other instrumentality
of any government, whether federal, state or local.

               “HSI” shall have the meaning set forth in the Preamble.

               “In the Money Options”
means (i) all issued and outstanding options for BAHHC Common Shares for which the applicable exercise price is
less than the Put Price and which are either vested as of the applicable Put Closing Date or may become vested in
accordance with their terms within six (6) months after the applicable Put Closing Date, and (ii) any BAHHC Common
Shares issued upon exercise of any options at any time on or after the applicable Put Notice Date through the date
immediately preceding the applicable Put Closing Date.

               “Initial Public Offering” means the initial underwritten public offering of common
stock by the Company pursuant to an effective registration statement on Form S-1 (or any successor
form) under the Security Act.

               “Lien” means any pledge, hypothecation, right of others, claim, security interest,
encumbrance, adverse claim or interest, voting trust agreement, interest, equity, option, lien,
right of first refusal, charge or other restriction or limitation.

3

 

               “LIFO Tax Adjustment Amount”
means, with respect to the tax distributions to be made by the Company on or after the Burns Put Closing Date with
regard to the income already recognized, and to be recognized, for tax purposes by the Company as a result of the
change from the LIFO to the FIFO inventory accounting method in accordance with Section 4.1 of the Operating
Agreement, the amount calculated by multiplying (x) the present value (discounted at the Discount Rate) of the
amount of tax liability to be borne by Burns with regard to that income pursuant to the last sentence of
Section 4.1 of the Operating Agreement, based on the Corporate Tax Rate (as defined in the Operating Agreement,
based on the operations of the Company as of the day immediately preceding the Burns Put Closing Date for the
purpose of determining allocation and apportionment) in effect for the relevant periods on the day immediately
preceding the Burns Put Closing Date, by (y) a fraction, (i) the denominator of which shall be the Effective
Percentage Interest (as defined in the Operating Agreement) of Burns immediately following the consummation of the
transactions contemplated by the Omnibus Agreement, and (ii) the numerator of which shall be the Effective Percentage
Interest represented by the Put Securities as of immediately following the consummation of the transactions contemplated
by the Omnibus Agreement.

               “Market Price” means the closing sale price per BAHHC Common Share on the applicable
Put Notice Date (or the nearest preceding business day).

               “Notice” shall have the meaning set forth in Section 3.2.

               “Oak Hill” means OHCM together with OHCP.

               “Oak Hill Divestiture Date” means the date upon which Oak Hill no longer owns any
“Securities”, as that term is defined in the Oak Hill Put Rights Agreement.

               “Oak Hill Put Closing” means the occurrence of a Put Closing (as defined in the Oak
Hill Put Rights Agreement) pursuant to the Oak Hill Put Rights Agreement.

               “Oak
Hill Put Notice” means the Put Notice as defined in the Oak
Hill Put Rights Agreement.

               “Oak Hill Put Price” means the Put Price (as defined in the Oak Hill Put Rights
Agreement).

               “Oak Hill Put Rights Agreement” means the Put Rights Agreement, dated as of the date
hereof, between HSI, Oak Hill and the Company.

               “OHCM” means Oak Hill Capital Management Partners II, L.P., a Delaware limited
partnership.

               “OHCP” means Oak Hill Capital Partners II, L.P., a Delaware limited partnership.

               “Omnibus Agreement” means the Omnibus Agreement, dated as of November 29, 2009, by and
among HSI, National Logistics Services, LLC, Oak Hill, WABC, Darby, Burns, the Company and the
other Persons party thereto.

               “Operating Agreement” means the Third Amended and Restated Limited Liability Company
Operating Agreement of the Company, dated as of the date hereof, between

4

 

WABC, OHCM, HSI, OHCP,
Darby, Burns and the other members party thereto, as amended from time to time in accordance with
the terms thereof.

               “Person” means an individual, a corporation, a partnership, a joint venture, a trust,
an unincorporated organization, a limited liability company or partnership, a government and any
agency or political subdivision thereof.

               “Post Divestiture Put Year” means any Put Year following the Oak Hill Divestiture
Date. For purposes of clarification, if such date occurs during any Put Year, then the first Post
Divestiture Put Year shall be the following Put Year.

               “Pre
Divestiture Put Year” means any Put Year beginning prior to
the first Post Divestiture
Put Year.

               “Put Interest Percentage” means a percentage equal to the number of BAHHC Common
Shares designated as Put Securities in the relevant Put Notice divided by the total number of BAHHC
Common Shares and Convertible Securities then issued and outstanding determined on a fully diluted
as-converted basis taking into account option dilution for
In the Money Options, in each case as calculated as of the Put Notice
Date (except as indicated in the definition of In the Money Options).

               “Put Notice” shall have the meaning set forth in Section 2.1(b).

               “Put Notice Date” means, with respect to each Put Notice, the date on which such Put
Notice is delivered to HSI.

               “Put Securities” shall have the meaning set forth in Section 2.1(b).

               “Put Year” means the one year period commencing on the fifth anniversary of the
Closing Date and ending on the date immediately prior to the sixth anniversary of the Closing Date
and each successive one year period thereafter.

               “Qualified Initial Public Offering” has the meaning given to such term in the
Registration Rights Agreement.

               “Securities Act” means the Securities Act of 1933, as amended, or any similar
successor federal statute, and the rules and regulations of the Commission thereunder, all as the
same shall be in effect at the time.

               “WABC” means W.A. Butler Company, a Delaware corporation, or its successor.

5

 

ARTICLE II

PUT RIGHTS

     2.1. Burns Put Right Grants and Mechanics.

          (a) HSI hereby grants to Burns the right (a “Burns Put Right”), at any time and from
time to time on or after the fifth anniversary of the Closing Date, to require HSI to purchase all
or any portion of the 205,635.72 BAHHC Common Shares owned by Burns on the
date hereof, on the terms and
subject to the conditions set forth in this Agreement.

          (b) Subject to Sections 2.5(a) through (c), Burns may exercise its Burns Put Right by delivery
of a written Notice (a “Put Notice”) to HSI, which Put Notice shall state that Burns is
exercising its Burns Put Right to require HSI to purchase the number and type of BAHHC Common
Shares specified in such Put Notice (the “Put Securities”)
and may, if such Put Notice is being delivered at any time prior to
the first anniversary of the Oak Hill Divestiture Date, state the
minimum number of Put Securities that would be acceptable to Burns
if all such Put Securities are greater than the Annual Burns Put
Limitation Amount.

     2.2. Determination of Fair Market Value. For purposes of calculating Burns Put Price
payable in connection with the exercise of any Burns Put Right, the Fair Market Value shall be
determined as follows:

       (a) Pre-QPO. If the Put Notice is delivered prior to a Qualified Initial Public
Offering, the Burns Put Price payable in connection with the exercise of any Burns Put Right shall
be determined as follows:

     (i) Mutual Agreement. Burns and HSI shall use all reasonable efforts
and negotiate in good faith to agree upon the Fair Market Value. If Burns and HSI
agree upon the Fair Market Value, then, subject to the conditions to closing set
forth in Section 2.4 below, Burns shall sell, transfer and convey, and HSI
shall purchase and accept, the Put Securities free and clear of all Liens at the
Burns Put Closing for the Burns Put Price calculated based on such agreed-upon Fair
Market Value.

     (ii) Dispute Procedures. (1) If Burns and HSI are unable to agree upon
the Fair Market Value pursuant to Section 2.2(a)(i) within twenty-one (21)
days of the Put Notice Date, then either party may request, by delivery of a written
Notice to the other party, an independent investment bank retained by the Company,
or, if such investment bank is not acceptable to Burns or HSI, another reputable
independent nationally recognized investment bank as to which HSI and Burns mutually
agree (the “Designated Investment Banker”), that the Designated Investment
Banker determine the Fair Market Value. If HSI and Burns are unable to agree upon
the selection of the Designated Investment Banker, then each shall select one
nationally recognized investment bank and the Designated Investment Banker shall be
selected by those two investment banks, whose determination of the Designated
Investment Banker will constitute an arbitral award that is final, binding and
non-appealable and upon which a judgment may be entered by a
court with jurisdiction thereover. The Designated Investment Banker shall
determine the Fair Market Value, using such method or methods of determining Fair
Market Value as it, in its sole discretion, shall determine; provided,
however, that in determining Fair Market Value, the Designated Investment
Banker shall (A) not include a discount for lack of control, minority interests,
lack of a public market in the Company’s securities or leverage levels, block sale
discounts or

6

 

otherwise take into account any contractual restrictions on the Company’s
ability to operate anywhere in the world or limiting HSI’s ability to consummate the
Burns Put Closing (other than as set forth in this Agreement), (B) consider, among
other things, the value that could be realized by a sophisticated seller seeking to
maximize the consideration to be received for the Put Securities, whether through a
private sale of 100% of the Company or a strategic combination or in an Initial
Public Offering (determined on a fully distributed basis) and assuming, for purposes
of the valuation, that the capital stock of the Company is widely held and no one
shareholder holds a control position), without taking into consideration any initial
public offering discount or underwriter’s discount or any other costs or expenses of
sale, and (C) consider, in addition to any other methods deemed by the Designated
Investment Banker, in its sole discretion, to be customary or appropriate, the
Enterprise Value Methodology. For the avoidance of doubt, the Designated
Investment Banker shall not consider or attribute any value (or negative value) to
any distribution advances by the Company provided for in Section 6.6(a)(ii) of the
Operating Agreement or tax liabilities relating to the change from the LIFO to the
FIFO inventory accounting method, which is the subject of the last sentence of
Section 4.1 of the Operating Agreement. Upon reasonable notice, the Designated
Investment Banker shall provide each of Burns and HSI the opportunity to make one
presentation (with representatives of the non-presenting party present) of
reasonable length to the Designated Investment Banker regarding their respective
views on the determination of Fair Market Value; provided that any materials
provided by any party to the Designated Investment Banker in connection with such
presentation shall be simultaneously provided to the other party. The Designated
Investment Banker shall issue its determination in writing to Burns and HSI (the
“Final Determination”) within forty-five (45) days of delivery of the
initial Notice to the Designated Investment Banker requesting such determination and
will constitute an arbitral award that is final, binding and non-appealable and upon
which judgment may be entered by a court with jurisdiction thereover.

     (2) Burns shall have fifteen (15) days after delivery of the Final
Determination (the “Decision Period”) to decide whether to (A) withdraw its
Put Notice or (B) require HSI to purchase the Put Securities indicated in its Put
Notice for a price equal to the Burns Put Price calculated based on the Fair Market
Value set forth in the Final Determination, which decision shall be furnished to HSI
by written Notice delivered prior to the expiration of the Decision Period,
notifying HSI of such decision (the “Final Notice”). If the Final Notice
indicates that Burns is withdrawing its Put Notice or if Burns fails to deliver a
Final Notice prior to the expiration of the Decision Period, then the Put Notice
shall be deemed to be irrevocably withdrawn and HSI shall not be required to
purchase the Put Securities specified in such Put Notice. Any Put Notice that is
withdrawn pursuant to this Section 2.2(a)(ii)(2) shall continue to be deemed
to have been delivered for purposes of Section 2.5(c).

          (b) Post-QPO. If the Put Notice is delivered after a Qualified Initial Public
Offering: (i) if the BAHHC Common Shares are then listed or quoted on NASDAQ or NYSE,

7

 

the Burns Put Price shall be equal to the Market Price, and (ii) if the BAHHC Common Shares
are not then listed or quoted on NASDAQ or NYSE, the Fair Market Value shall be determined in
accordance with Section 2.2(a). In lieu of exercising a Burns Put Right hereunder, Burns
may, subject to any restriction set forth in the Registration Rights Agreement and any applicable
securities law restrictions, sell any or all of their respective BAHHC Common Shares on the open
market pursuant to Rule 144 of the Securities Act or the Registration Rights Agreement.

     2.3. Payment of Burns Put Price. The Burns Put Price payable by HSI at the Burns Put
Closing shall be payable in a single cash payment by wire transfer of immediately available funds
to an account designated by Burns in writing at least two (2) days prior to the Burns Put Closing.

     2.4. Burns Put Closing; Conditions Precedent. 

          (a) HSI and Burns shall consummate the sale of the Put Shares (the “Burns Put
Closing”) as soon as reasonably practicable after the delivery of the Final Notice to HSI, but
in no event later than thirty (30) days after delivery of the Final Notice (the “Burns Put
Closing Date”), subject in all respects to the satisfaction of the conditions set forth in
Sections 2.4(b) and 2.4(c).

          (b) HSI’s obligations to purchase the Put Securities at a Burns Put Closing shall be expressly
subject to the fulfillment or express written waiver by HSI of the following conditions on or prior
to the applicable Burns Put Closing Date:

     (i) HSI shall have received from Burns certificates or other instruments
representing the Put Securities, together with unit, stock or other appropriate
powers duly endorsed with respect thereto, if applicable, together with and any other documentation
reasonably requested by HSI in order to confirm that such Put Shares, and all rights
in respect thereof (including, without limitation, all economic and voting rights)
are being transferred to HSI free and clear of all Liens.

     (ii) There shall not be any order of any Governmental Authority restraining or
invalidating the transactions which are the subject of this Agreement.

     (iii) The purchase and sale of the Put Securities at the Burns Put Closing
would not violate the Securities Act or any state securities or “blue sky” laws
applicable to Burns, HSI, the Company or the Put Securities.

          (c) Burns’s obligations to sell the Put Securities at a Burns Put Closing shall be expressly
subject to the fulfillment or express written waiver by Burns of the following conditions on or
prior to the applicable Burns Put Closing Date:

     (i) HSI shall have paid the Burns Put Price.

8

 

     (ii) There shall not be any order of any Governmental Authority restraining or
invalidating the transactions which are the subject of this Agreement.

     (iii) The purchase and sale of the Put Securities at the Burns Put Closing
would not violate the Securities Act or any state securities or “blue sky” laws
applicable to Burns, HSI, the Company or the Put Securities.

          (d) If any of the conditions set forth in Section 2.4(b) and 2.4(c) are not or are not
reasonably expected to be satisfied on the Burns Put Closing Date, HSI and Burns shall cooperate in
good faith to cause such conditions to be satisfied.

     2.5. Additional Terms and Conditions Applicable to Burns Put Rights.

          (a) During any Pre Divestiture Put Year, Burns shall only be permitted to exercise its Burns
Put Right  during the 30-Day True-Up Period.

          (b) In any Put Year, HSI shall not be required to pay, in the aggregate, Burns Put Prices or
acquire, in the aggregate, that number of Put Securities, as applicable, in excess of the
applicable Annual Burns Put Limitation Amount. If the Burns Put Price otherwise payable by HSI, or
the number of Put Securities otherwise to be acquired by HSI, on a Burns Put Closing Date, when
combined with all other Burns Put Prices and Oak Hill Put Prices paid by HSI during the Put Year in
which such Burns Put Closing Date is to occur, would exceed the Annual Burns
Put Limitation Amount, then HSI shall only be obligated to purchase that portion of the Put
Securities so that, when combined with all other Burns Put Prices paid by HSI and Put Securities
acquired by HSI during the Put Year in which such Burns Put Closing Date is to occur (or deemed to
occur), the Annual Burns Put Limitation Amount is not exceeded, and the number of Put Securities to
be acquired on such Burns Put Closing Date shall be reduced accordingly. If Burns exercises its
Burns Put Right during a 30-Day True-Up Period pursuant to sub-section (b) of the definition of 30-Day True-Up Period, then the prior year’s Annual Burns Put Limitation Amount
shall be applicable; provided, however, that, if Oak Hill delivers an Oak Hill Put Notice following the
delivery of a Put Notice by Burns but prior to the applicable Put Closing therefor, then (x) the Put Closing in
respect of such Put Notice from Burns  shall be delayed so that such Put Closing shall occur
immediately following the applicable Oak Hill Put Closing, (y) the
Fair Market Value or Market Price, as applicable, shall equal the value or price used in connection with the applicable Oak Hill Put
Closing and (z) if, after giving effect to such Oak Hill Put Closing, the number of Put Securities that would be within the applicable Annual
Burns Put Limitation Amount is less than the minimum number specified
in the Put Notice, then Burns may withdraw such Put Notice and the
next Put Notice delivered by Burns during the remainder of such Put
Year shall not be subject to the provisions of Section 2.5(c).

          (c) No Put Notice may be delivered if a Put Notice has already been delivered during the
immediately preceding twelve (12) month period, and any such Put Notice shall be void ab initio;
provided, however, if a Put Notice is withdrawn pursuant to Sections
2.2(a)(ii)(2) then Burns may deliver a Put Notice after the date that is six (6) months
following the expiration of the applicable Decision Period in the case of Section
2.2(a)(ii)(2).

          (d) The Company shall, and HSI and Burns shall cause the Company to, provide the Designated
Investment Banker with access, upon reasonable notice and during normal business hours, to
management of the Company and to such documents and information as it shall reasonably request,
including, without limitation, the most recently approved Company Budget and projections for the
Company’s next fiscal year presented by Company management to the Company Board. Any access under
this Section 2.5(d) shall be subject to such limitations

9

 

as the Company may reasonably require to prevent the disclosure of non-public information
and/or the material disruption of the business of the Company, including, without limitation, the
execution of a non-disclosure agreement by the Designated Investment Banker in form and substance
reasonably satisfactory to the Company. The Company shall provide reasonable prior written notice
to HSI and Burns of any access to be provided by the Company to the Designated Investment Banker.
HSI, Burns and their respective representatives shall have the right to accompany the Designated
Investment Banker on any visits to Company’s facilities or in any meetings between the Designated
Investment Banker and management of the Company.

          (e) All fees, costs and expenses of the Designated Investment Banker incurred in connection
with the determination of the Burns Put Price hereunder shall be borne by the Company.

          (f) The Burns Put Rights granted hereunder are personal to Burns and may not be transferred or
assigned by Burns other than in accordance with Section 3.8 hereof.

ARTICLE III

MISCELLANEOUS

     3.1. Choice of Law; Forum; Waiver of Jury Trial. This Agreement and all claims and
controversies hereunder (whether based on contract, tort or any other theory) shall be governed by
and construed in accordance with the internal laws of the state of New York, without regard to the
choice of law provisions thereof. Any proceeding arising out of or relating to this Agreement
shall be brought in the courts of the state of New York sitting in the County of New York, State of
New York, or, if it has or can acquire jurisdiction, in the United States District Court for the
Southern District of New York. Each party hereby expressly submits to the personal jurisdiction
and venue of such courts as provided above for the purposes thereof and expressly waives any claim
of improper venue and any claim that such courts are an inconvenient forum. Each party hereby
irrevocably consents to the service of process of any of the aforementioned courts in any such
suit, action or proceeding by the mailing of copies thereof by registered or certified mail,
postage prepaid, to the address set forth or referred to in Section 3.2. EACH PARTY HERETO
HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL
BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT
OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY).
EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS
REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION,
SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE
BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND
CERTIFICATIONS IN THIS SECTION.

     3.2. Notices. All notices, requests, demands, approvals, consents, waivers and other
communications required or permitted to be given under this Agreement (each, a “Notice”)
shall be in writing and delivered in person, by facsimile transmission (with a Notice

10

 

contemporaneously given by another method specified in this Section 3.2) or by
overnight courier service, at the following addresses (or at such other address for a party as
shall be specified to the other parties by like Notice). All such Notices shall only be duly given
and effective upon receipt (or refusal of receipt).

	 	(a)	 	If to HSI, to:

Henry Schein, Inc.

135 Duryea Road

Melville, NY 11747

Facsimile: (631) 843-5660

Attn: General Counsel

With a copy (which shall not constitute notice) to:

Proskauer Rose LLP

1585 Broadway

New York, NY 10036

Facsimile: (212) 969-2900

Attn: Steven Kirshenbaum, Esq.

	 	(b)	 	If to Burns, to:

c/o Darby Group Companies, Inc.

300 Jericho Quadrangle

Jericho, NY 11753

Facsimile: (516) 688-2813

Attn: President

with a copy (which shall not constitute notice) to:

Salon, Marrow, Dyckman Newman & Broudy LLP

292 Madison Avenue

New York, NY 10017

Facsimile: (212) 661-3339

Attn: Joel Salon, Esq.

     3.3. Amendments. Any provision of this Agreement may be modified, amended or waived
only by a writing signed by each of the parties hereto. For the purposes of this Agreement and all
agreements executed pursuant hereto, no course of dealing between or among any of the parties
hereto and no delay on the part of any party hereto in exercising any rights hereunder or
thereunder shall operate as a waiver of the rights hereof and thereof.

     3.4. Severability. If any provision of this Agreement shall be held to be illegal,
invalid or unenforceable, such illegality, invalidity or unenforceability shall attach only to such
provision and shall not in any manner affect or render illegal, invalid or unenforceable any other

11

 

provision of this Agreement, and this Agreement shall be carried out as if any such illegal,
invalid or unenforceable provision were not contained herein.

     3.5. Integration. This Agreement, including the exhibits, documents and instruments
referred to herein or therein, constitutes the entire agreement among the parties with respect to
the subject matter hereof.

     3.6. Construction. The Article and Section headings used or contained in this
Agreement are for convenience of reference only and shall not affect the construction of this
Agreement. The parties have participated jointly in the negotiation and drafting of this Agreement
with counsel sophisticated in investment transactions. In the event an ambiguity or question of
intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the
parties and no presumption or burden of proof shall arise favoring or disfavoring any party by
virtue of the authorship of any provisions of this Agreement.

     3.7. Counterparts. This Agreement may be executed in two or more counterparts, each
of which shall be deemed an original, but all of which together shall constitute one and the same
instrument.

     3.8. Successors and Assigns. The provisions of this Agreement shall be binding upon
and inure to the benefit of the parties hereto and their respective successors and permitted
assigns; provided, that no party may directly or indirectly assign, delegate or otherwise transfer
any of its rights or obligations under this Agreement without the prior written consent of HSI and
Burns. Notwithstanding the foregoing, (a) HSI shall be entitled to assign its rights and
obligations under this Agreement, without the consent of any other party hereto, to any Affiliate
of HSI; and (b) Burns shall be entitled to assign its rights and obligations under this Agreement,
without the consent of any other party hereto to its Permitted Primary Transferees;
provided, however, that (i) one Person reasonably acceptable to HSI, shall be
appointed as agent with full power and authority to act conclusively and timely for and on behalf
of all such Permitted Primary Transferees with respect to their rights and obligations hereunder,
on terms and conditions reasonably satisfactory to HSI and (ii) HSI shall not incur or become
subject to any additional obligations as a result of any such assignment. For the avoidance of
doubt, in the event that HSI (i) consolidates with or merges into any other person and shall not be
the continuing or surviving entity in such consolidation or merger or (ii) transfers all or
substantially all of its properties and assets to any person, then, in each case, the successors
and purchasers of HSI or HSI’s properties and assets, as appropriate, shall agree to fulfill and
comply with the obligations set forth in this Agreement. Notwithstanding any assignment by any
party of its obligations hereunder, such assigning party shall remain primarily liable for all
obligations so assigned.

[Signature Page Follows.]

12

 

     IN WITNESS WHEREOF, the parties hereto have duly executed and delivered this Agreement on the
date first above written.

	 	 	 	 	 	 	 
	 	 	HENRY SCHEIN, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Michael Ettinger 	 	 
	 

	 	Name:
	 	Michael Ettinger

	 	 
	 

	 	Title:	 	Senior Vice President and Secretary 	 	 
	 
	 	 	 	 	 	 
	 	 	BURNS VETERINARY SUPPLY, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Michael Caputo	 	 
	 

	 	Name:
	 	Michael Caputo 

	 	 
	 

	 	Title:	 	President 	 	 
	 
	 	 	 	 	 	 
	 	 	BUTLER ANIMAL HEALTH HOLDING COMPANY, LLC

(solely with respect to Sections 2.5(d)

and 2.5(e) of this Agreement)	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Kevin R. Vasquez 	 	 
	 

	 	Name:
	 	Kevin R. Vasquez 

	 	 
	 

	 	Title:	 	CEO and President 	 	 

[Signature Page to Burns Put Rights Agreement]exv4w1

Exhibit 4.1

SECURITIES PURCHASE AGREEMENT

     This Securities Purchase Agreement (this “Agreement”) is dated as of January 4, 2010,
between ADVENTRX Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each
purchaser identified on the signature pages hereto (each, including its successors and assigns, a
“Purchaser” and collectively, the “Purchasers”).

     WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an
effective registration statement under the Securities Act of 1933, as amended (the “Securities
Act”), the Company desires to issue and sell to each Purchaser, and each Purchaser, severally
and not jointly, desires to purchase from the Company, securities of the Company as more fully
described in this Agreement.

     NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for
other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged,
the Company and each Purchaser agree as follows:

ARTICLE I.

DEFINITIONS

     1.1 Definitions. In addition to the terms defined elsewhere in this Agreement: (a)
capitalized terms that are not otherwise defined herein have the meanings given to such terms in
the Certificate of Designation (as defined herein), and (b) the following terms have the meanings
set forth in this Section 1.1:

	 	 	“Acquiring Person” shall have the meaning ascribed to such term in Section 4.7.

     “Action” shall have the meaning ascribed to such term in Section 3.1(j).

     “Affiliate” means any Person that, directly or indirectly through one or more
intermediaries, controls or is controlled by or is under common control with a Person, as
such terms are used in and construed under Rule 405 under the Securities Act.

     “Board of Directors” means the board of directors of the Company.

     “Business Day” means any day except any Saturday, any Sunday, any day which is
a federal legal holiday in the United States or any day on which banking institutions in the
State of New York are authorized or required by law or other governmental action to close.

     “Certificate of Designation” means the Certificate of Designation to be filed
prior to the Closing by the Company with the Secretary of State of Delaware, in the form of
Exhibit A attached hereto.

     “Closing” means the closing of the purchase and sale of the Securities pursuant
to Section 2.1.

     “Closing Date” means the Trading Day on which all of the Transaction Documents
have been executed and delivered by the applicable parties thereto, and all conditions
precedent to (i) the Purchasers’ obligations to pay the Subscription Amount and (ii) the
Company’s obligations to deliver the Securities, in each case, have been

 

 

satisfied or waived, but in no event later than the third Trading Day following the
date hereof.

     “Commission” means the United States Securities and Exchange Commission.

     “Common Stock” means the common stock of the Company, par value $0.001 per
share, and any other class of securities into which such securities may hereafter be
reclassified or changed.

     “Common Stock Equivalents” means any securities of the Company or the
Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock,
including, without limitation, any debt, preferred stock, rights, options, warrants or other
instrument that is at any time convertible into or exercisable or exchangeable for, or
otherwise entitles the holder thereof to receive, Common Stock.

     “Company Counsel” means DLA Piper LLP (US), with offices located at 4365
Executive Drive, Suite 1100, San Diego, CA 92121.

     “Disclosure Schedules” means the Disclosure Schedules of the Company delivered
concurrently herewith.

     “Evaluation Date” shall have the meaning ascribed to such term in Section
3.1(r).

     “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the
rules and regulations promulgated thereunder.

     “Exempt Issuance” means the issuance of (a) a Common Stock purchase warrant to
Rodman & Renshaw LLC, as compensation for its services as the Company’s placement agent, and
 shares of Common Stock issuable upon exercise thereof, (b) shares of Common Stock, options
or other equity awards to employees, officers, directors or consultants of the Company
pursuant to any equity incentive plan duly adopted for such purpose, by a majority of the
non-employee members of the Board of Directors or a majority of the members of a committee
of non-employee directors established for such purpose, (c) securities upon the exercise or
exchange of or conversion of any Securities issued hereunder and/or other securities
exercisable or exchangeable for or convertible into shares of Common Stock issued and
outstanding on the date of this Agreement, provided that such securities have not been
amended since the date of this Agreement to increase the number of such securities or to
decrease the exercise price, exchange price or conversion price of such securities, and (d)
securities issued pursuant to acquisitions or strategic transactions approved by a majority
of the disinterested directors of the Company, provided that any such issuance shall only be
to a Person (or to the equityholders of a Person) which is, itself or through its
subsidiaries, an operating company or an asset in a business synergistic with the business
of the Company and shall provide to the Company additional benefits in addition to the
investment of funds, but shall not include a transaction in which the Company is issuing
securities primarily for the purpose of raising capital or to an entity whose primary
business is investing in securities.

     “FDA” shall have the meaning ascribed to such term in Section 3.1(gg).

     “FDCA” shall have the meaning ascribed to such term in Section 3.1(gg).

2

 

     “GAAP” shall have the meaning ascribed to such term in Section 3.1(h).

     “Indebtedness” shall have the meaning ascribed to such term in Section 3.1(z).

     “Intellectual Property Rights” shall have the meaning ascribed to such term in
Section 3.1(o).

     “Liens” means a lien, charge, security interest, encumbrance, right of first
refusal, preemptive right or other restriction other than restrictions imposed by securities
laws.

     “Make-Whole Payment” shall have the meaning ascribed such term in the
Certificate of Designation.

     “Material Adverse Effect” shall have the meaning assigned to such term in
Section 3.1(b).

     “Material Permits” shall have the meaning ascribed to such term in Section
3.1(m).

     “Maximum Rate” shall have the meaning ascribed to such term in Section 5.17.

     “Person” means an individual or corporation, partnership, trust, incorporated
or unincorporated association, joint venture, limited liability company, joint stock
company, government (or an agency or subdivision thereof) or other entity of any kind.

     “Pharmaceutical Product” shall have the meaning ascribed to such term in
Section 3.1(gg).

     “Preferred Stock” means the up to 19,000 shares of the Company’s Series E
Convertible Preferred Stock issued hereunder having the rights, preferences, privileges and
limitations set forth in the Certificate of Designation, in the form of Exhibit A
hereto.

     “Proceeding” means an action, claim, suit, investigation or proceeding
(including, without limitation, an informal investigation or partial proceeding, such as a
deposition), whether commenced or threatened.

     “Prospectus” means the final prospectus filed for the Registration Statement.

     “Prospectus Supplement” means the supplement to the Prospectus complying with
Rule 424(b) of the Securities Act that is filed with the Commission and delivered by the
Company to each Purchaser before or at the Closing.

     “Purchaser Party” shall have the meaning ascribed to such term in Section 4.10.

     “Registration Statement” means the effective registration statements on Form
S-3 with the Commission which registers the sale of the Preferred Stock, Warrants and
Underlying Shares to the Purchasers.

     “Required Approvals” shall have the meaning ascribed to such term in Section
3.1(e).

3

 

     “Required Minimum” means, as of any date, the maximum aggregate number of
 shares of Common Stock then issued or potentially issuable in the future pursuant to the
Transaction Documents, including any Underlying Shares issuable upon exercise in full of all
Warrants or conversion in full of all shares of Preferred Stock, ignoring any conversion or
exercise limits set forth therein.

     “Rule 144” means Rule 144 promulgated by the Commission pursuant to the
Securities Act, as such Rule may be amended from time to time, or any similar rule or
regulation hereafter adopted by the Commission having substantially the same effect as such
Rule.

     “Rule 424” means Rule 424 promulgated by the Commission pursuant to the
Securities Act, as such Rule may be amended or interpreted from time to time, or any similar
rule or regulation hereafter adopted by the Commission having substantially the same purpose
and effect as such Rule.

     “SEC Reports” shall have the meaning ascribed to such term in Section 3.1(h).

     “Securities” means the Preferred Stock, the Warrants and the Underlying Shares.

     “Securities Act” means the Securities Act of 1933, as amended, and the rules
and regulations promulgated thereunder.

     “Short Sales” means all “short sales” as defined in Rule 200 of Regulation SHO
under the Exchange Act (but shall not be deemed to include the location and/or reservation
of borrowable shares of Common Stock).

     “Stated Value” means $1,000 per share of Preferred Stock.

     “Subscription Amount” means, as to each Purchaser, the aggregate amount to be
paid for the units of Preferred Stock and Warrants purchased hereunder as specified below
such Purchaser’s name on the signature page of this Agreement and next to the heading
“Subscription Amount,” in United States dollars and in immediately available funds.

     “Subsidiary” means any subsidiary of the Company as set forth on Schedule
3.1(a) and shall, where applicable, also include any direct or indirect subsidiary of
the Company formed or acquired after the date hereof.

     “Trading Day” means a day on which the principal Trading Market for the Common
Stock is open for trading.

     “Trading Market” means any of the following markets or exchanges on which the
Common Stock is listed or quoted for trading on the date in question: the NYSE AMEX, the
Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New
York Stock Exchange or the OTC Bulletin Board (or any successors to any of the foregoing).

     “Transaction Documents” means this Agreement, the Certificate of Designation,
the Warrants, all exhibits and schedules thereto and hereto and any other documents or
agreements executed in connection with the transactions contemplated hereunder.

4

 

     “Transfer Agent” means American Stock Transfer & Trust Company LLC, the current
transfer agent of the Company, with a mailing address of 6201 15th Avenue, 2nd Floor,
Brooklyn, NY 11219 and a facsimile number of (718) 921-8310, and any successor transfer
agent of the Company.

     “Underlying Shares” means the shares of Common Stock issued and issuable upon
conversion or redemption of the Preferred Stock and upon exercise of the Warrants.

     “Variable Rate Transaction” shall have the meaning ascribed to such term in
Section 4.13(b).

     “Warrants” means, collectively, the Common Stock purchase warrants delivered to
the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which Warrants shall
be exercisable commencing on their date of issuance and have a term of exercise equal to
thirty (30) months from the date they first become exercisable, in the form of
Exhibit B attached hereto.

     “Warrant Shares” means the shares of Common Stock issuable upon exercise of the
Warrants.

     “WS” means Weinstein Smith LLP with offices located at 420 Lexington Avenue,
Suite 2620, New York, New York 10170-0002.

ARTICLE II.

PURCHASE AND SALE

     2.1 Closing. On the Closing Date, upon the terms and subject to the conditions set
forth herein, substantially concurrent with the execution and delivery of this Agreement by the
parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to
purchase, up to an aggregate of $19,000,000 of shares of Preferred Stock with an aggregate Stated
Value for each Purchaser equal to such Purchaser’s Subscription Amount as set forth on the
signature page hereto executed by such Purchaser, and Warrants as determined by pursuant to Section
2.2(a). The aggregate number of shares of Preferred Stock sold hereunder shall be up to 19,000.
At the Closing, each Purchaser shall deliver to the Company via wire transfer or a certified check
of immediately available funds equal to its Subscription Amount, and the Company shall deliver to
each Purchaser its respective shares of Preferred Stock and Warrants, as determined pursuant to
Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in
Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set
forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of WS or such other location
as the parties shall mutually agree.
Notwithstanding anything herein to the contrary, in the event that a Purchaser
delivers a Notice of Conversion (as defined in the Certificate of Designation)
to the Company after the execution hereof and before the Closing, the Company shall
 issue the Conversion Shares to such Purchaser on the same terms as set forth in the Certificate
 of Designations and such issuance of Conversions Shares shall not otherwise be subject to the
 occurrence of the Closing or Section 2.3 hereof.

     2.2 Deliveries.

     (a) On or prior to the Closing Date, the Company shall deliver or cause to be delivered
to each Purchaser the following:

     (i) this Agreement duly executed by the Company;

     (ii) a legal opinion of Company Counsel, substantially in the form to be
mutually agreed upon by the parties hereto;

5

 

     (iii) a certificate evidencing a number of shares of Preferred Stock equal to
such Purchaser’s Subscription Amount divided by the Stated Value, registered in the
name of such Purchaser and evidence of the filing and acceptance of the Certificate
of Designation from the Secretary of State of Delaware;

     (iv) a Warrant registered in the name of such Purchaser to purchase up to a
number of shares of Common Stock equal to 25% of the number of Conversion Shares
initially issuable to such Purchaser upon conversion of all of such Purchaser’s
Preferred Stock, with an exercise price equal to $0.3499, subject to adjustment as
provided by the terms thereof;

     (v) an escrow agreement in form and substance reasonably satisfactory to the
Company and the Purchasers pursuant to which the Make-Whole Payment shall be
deposited; and

     (vi) the Prospectus and Prospectus Supplement (which may be delivered in
accordance with Rule 172 under the Securities Act).

     (b) On or prior to the Closing Date, each Purchaser shall deliver or cause to be
delivered to the Company the following:

     (i) this Agreement duly executed by such Purchaser;

     (ii) an escrow agreement in form and substance
reasonably satisfactory to the Company and the Purchasers pursuant to
which the Make-Whole Payment shall be deposited; and

     (iii) such Purchaser’s Subscription Amount by wire transfer to the account as
specified in writing by the Company, of which the Make-Whole Payment shall be
deposited directly in the above-referenced escrow account.

     2.3 Closing Conditions.

     (a) The obligations of the Company hereunder in connection with the Closing are subject
to the following conditions being met:

     (i) the accuracy in all material respects when made and on the Closing Date of
the representations and warranties each Purchaser contained herein (unless as of a
specific date therein);

     (ii) all obligations, covenants and agreements of each Purchaser required to be
performed at or prior to the Closing Date shall have been performed; and

     (iii) the delivery by each Purchaser of the items set forth in Section 2.2(b)
of this Agreement.

     (b) The respective obligations of the Purchasers hereunder in connection with the
Closing are subject to the following conditions being met:

6

 

     (i) the accuracy in all material respects when made and on the Closing Date of
the representations and warranties of the Company contained herein (unless as of a
specific date therein);

     (ii) all obligations, covenants and agreements of the Company required to be
performed at or prior to the Closing Date shall have been performed;

     (iii) the delivery by the Company of the items set forth in Section 2.2(a) of
this Agreement;

     (iv) there shall have been no Material Adverse Effect with respect to the
Company since the date hereof; and

     (v) from the date hereof to the Closing Date, trading in the Common Stock shall
not have been suspended by the Commission or the Company’s principal Trading Market
(except for any suspension of trading of limited duration agreed to by the Company,
which suspension shall be terminated prior to the Closing), and, at any time prior
to the Closing Date, trading in securities generally as reported by Bloomberg L.P.
shall not have been suspended or limited, or minimum prices shall not have been
established on securities whose trades are reported by such service, or on any
Trading Market, nor shall a banking moratorium have been declared either by the
United States or New York State authorities nor shall there have occurred any
material outbreak or escalation of hostilities or other national or international
calamity of such magnitude in its effect on, or any material adverse change in, any
financial market which, in each case, in the reasonable judgment of each Purchaser,
makes it impracticable or inadvisable to purchase the Securities at the Closing.

ARTICLE III.

REPRESENTATIONS AND WARRANTIES

     3.1 Representations and Warranties of the Company. Except as set forth or
incorporated by reference into the Registration Statement, the Prospectus, the Prospectus
Supplement or the Disclosure Schedules, which disclosures in such filings with the Commission and
in the Disclosure Schedules shall be deemed a part hereof and shall qualify any representation or
otherwise made herein to the extent of the disclosure contained in such filings with the Commission
or in the Disclosure Schedule corresponding to this Section 3.1, the Company hereby makes the
following representations and warranties to each Purchaser:

     (a) Subsidiaries. All of the direct and indirect subsidiaries of the Company
are set forth on Schedule 3.1(a). The Company owns, directly or indirectly, all of
the capital stock or other equity interests of each Subsidiary free and clear of any Liens,
and all of the issued and outstanding shares of capital stock of each Subsidiary are validly
issued and are fully paid, non-assessable and free of preemptive and similar rights to
subscribe for or purchase securities. If the Company has no subsidiaries, all other
references to the Subsidiaries or any of them in the Transaction Documents shall be
disregarded.

     (b) Organization and Qualification. The Company and each of the Subsidiaries
is an entity duly incorporated or otherwise organized, validly existing and in

7

 

good standing under the laws of the jurisdiction of its incorporation or organization,
with the requisite power and authority to own and use its properties and assets and to carry
on its business as currently conducted. Neither the Company nor any Subsidiary is in
violation nor default of any of the provisions of its respective certificate or articles of
incorporation, bylaws or other organizational or charter documents. Each of the Company and
the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business
conducted or property owned by it makes such qualification necessary, except where the
failure to be so qualified or in good standing, as the case may be, could not reasonably be
expected to result in: (i) a material adverse effect on the legality, validity or
enforceability of any Transaction Document, (ii) a material adverse change in the results of
operations, assets, business, prospects or condition (financial or otherwise) of the Company
and the Subsidiaries, taken as a whole, from that set forth or incorporated by reference in
the Prospectus and Prospectus Supplement, or (iii) a material adverse effect on the
Company’s ability to perform in any material respect on a timely basis its obligations under
any Transaction Document (any of (i), (ii) or (iii), a “Material Adverse Effect”)
and no Proceeding has been instituted or, to the knowledge of the Company, threatened in any
such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail
such power and authority or qualification.

     (c) Authorization; Enforcement. The Company has the requisite corporate power
and authority to enter into and to consummate the transactions contemplated by each of the
Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of each of the Transaction Documents by the Company and the
consummation by it of the transactions contemplated hereby and thereby have been duly
authorized by all necessary action on the part of the Company and no further action is
required by the Company, the Board of Directors or the Company’s stockholders in connection
therewith other than in connection with the Required Approvals. Each Transaction Document
to which it is a party has been (or upon delivery will have been) duly executed by the
Company and, when delivered in accordance with the terms hereof and thereof, will constitute
the valid and binding obligation of the Company enforceable against the Company in
accordance with its terms, except: (i) as limited by general equitable principles and
applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors’ rights generally, (ii) as limited by laws
relating to the availability of specific performance, injunctive relief or other equitable
remedies and (iii) insofar as indemnification and contribution provisions may be limited by
applicable law.

     (d) No Conflicts. The execution, delivery and performance by the Company of
the Transaction Documents, the issuance and sale of the Securities and the consummation by
it of the transactions contemplated hereby and thereby to which it is a party do not and
will not: (i) conflict with or violate any provision of the Company’s or any Subsidiary’s
certificate or articles of incorporation, bylaws or other organizational or charter
documents, (ii) conflict with, or constitute a default (or an event that with notice or
lapse of time or both would become a default) under, result in the creation of any Lien upon
any of the properties or assets of the Company or any Subsidiary, or give to others any
rights of termination, amendment, acceleration or cancellation (with or without notice,
lapse of time or both) of, any agreement, credit facility, debt or other instrument
(evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the
Company or any Subsidiary is a party or by which any property or asset of the

8

 

Company or any Subsidiary is bound or affected, or (iii) subject to the Required
Approvals, conflict with or result in a violation of any law, rule, regulation, order,
judgment, injunction, decree or other restriction of any court or governmental authority to
which the Company or a Subsidiary is subject (including federal and state securities laws
and regulations), or by which any property or asset of the Company or a Subsidiary is bound
or affected; except in the case of each of clauses (ii) and (iii), such as could not
reasonably be expected to result in a Material Adverse Effect.

     (e) Filings, Consents and Approvals. The Company is not required to obtain any
consent, waiver, authorization or order of, give any notice to, or make any filing or
registration with, any court or other federal, state, local or other governmental authority
or other Person in connection with the execution, delivery and performance by the Company of
the Transaction Documents, other than: (i) the filings required pursuant to Section 4.6 of
this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, (iii) the
filing of application(s) to and approval by the NYSE Amex LLC for the listing of the
Underlying Shares for trading thereon in the time and manner required thereby, (iv) the
filing with the Secretary of State of the State of Delaware of the Certificate of
Designation, (v) an approval or waiver under that certain Rights Agreement, dated July 27,
2005, as amended (the “Rights Agreement”), and (vi) such filings as are required to
be made under applicable state securities laws and the rules and regulations of the
Financial Industry Regulatory Authority (FINRA) (collectively, the “Required
Approvals”).

     (f) Issuance of the Securities; Registration. The Securities are duly
authorized and, the Preferred Stock and Warrants, when issued and paid for in accordance
with the applicable Transaction Documents, will be duly and validly issued, fully paid and
nonassessable, free and clear of all Liens imposed by the Company. The Underlying Shares,
when issued in accordance with the terms of the applicable Transaction Documents, will be
validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the
Company. The Company has reserved from its duly authorized capital stock a number of shares
of Common Stock for issuance of the Underlying Shares at least equal to the Required Minimum
on the date hereof. The Company has prepared and filed the Registration Statement in
conformity with the requirements of the Securities Act, which became effective on June 4,
2009 (the “Effective Date”), including the Prospectus, and such amendments and
supplements thereto as may have been required to the date of this Agreement. The
Registration Statement is effective under the Securities Act and no stop order preventing or
suspending the effectiveness of the Registration Statement or suspending or preventing the
use of the Prospectus has been issued by the Commission and no proceedings for that purpose
have been instituted or, to the knowledge of the Company, are threatened by the Commission.
The Company, if required by the rules and regulations of the Commission, proposes to file
the Prospectus, with the Commission pursuant to Rule 424(b). At the time the Registration
Statement and any amendments thereto became effective, at the date of this Agreement and at
the Closing Date, the Registration Statement and any amendments thereto conformed and will
conform in all material respects to the requirements of the Securities Act and did not and
will not contain any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary to make the statements therein not misleading;
and the Prospectus and any amendments or supplements thereto, at time the Prospectus or any
amendment or supplement thereto was issued and at the Closing Date, conformed and will
conform in

9

 

all material respects to the requirements of the Securities Act and did not and will
not contain an untrue statement of a material fact or omit to state a material fact
necessary in order to make the statements therein, in light of the circumstances under which
they were made, not misleading.

     (g) Capitalization. The capitalization of the Company is as set forth in the
Prospectus and the Prospectus Supplement. The Company has not issued any capital stock since
its most recently filed periodic report under the Exchange Act, other than pursuant to the
exercise of employee stock options under the Company’s equity incentive plans, the issuance
of shares of Common Stock to employees pursuant to the Company’s employee stock purchase
plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding
as of the date of the most recently filed periodic report under the Exchange Act. Except as
set forth in the Rights Agreement, no Person has any right of first refusal, preemptive
right, right of participation, or any similar right to participate in the transactions
contemplated by the Transaction Documents. Except (i) as a result of the purchase and sale
of the Securities, (ii) pursuant to the Company’s equity incentive plans, (iii) pursuant to
agreements or instruments, including the Rights Agreement, filed as exhibits to SEC Reports
incorporated by reference into the Prospectus Supplement, and (iv) pursuant to the warrant
to be issued to Rodman & Renshaw LLC as compensation for its services as placement agent to
the Company, as a result of the purchase and sale of the Securities, there are no
outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities, rights or obligations convertible into or
exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire
any shares of Common Stock, or contracts, commitments, understandings or arrangements by
which the Company or any Subsidiary is or may become bound to issue additional shares of
Common Stock or Common Stock Equivalents. The issuance and sale of the Securities will not
obligate the Company to issue shares of Common Stock or other securities to any Person
(other than the Purchasers and the Company’s placement agent) and will not result in a right
of any holder of Company securities to adjust the exercise, conversion, exchange or reset
price under any of such securities. All of the outstanding shares of capital stock of the
Company are validly issued, fully paid and nonassessable, have been issued in compliance
with all federal and state securities laws, and none of such outstanding shares was issued
in violation of any preemptive rights or similar rights to subscribe for or purchase
securities. Except for the Required Approvals, no further approval or authorization of any
stockholder, the Board of Directors or others is required for the issuance and sale of the
Securities. There are no stockholders agreements, voting agreements or other similar
agreements with respect to the Company’s capital stock to which the Company is a party or,
to the knowledge of the Company, between or among any of the Company’s stockholders.

     (h) SEC Reports; Financial Statements. The Company has filed all reports,
schedules, forms, statements and other documents required to be filed by the Company under
the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d)
thereof, for the two years preceding the date hereof (or such shorter period as the Company
was required by law or regulation to file such material) (the foregoing materials, including
the exhibits thereto and documents incorporated by reference therein, together with the
Registration Statement, the Prospectus and the Prospectus Supplement, being collectively
referred to herein as the “SEC Reports”) on a timely basis or has received a valid
extension of such time of filing and has filed any such SEC Reports prior

10

 

to the expiration of any such extension. As of their respective dates, the SEC Reports
complied in all material respects with the requirements of the Securities Act and the
Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue
statement of a material fact or omitted to state a material fact required to be stated
therein or necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading. The Company has never been an
issuer subject to Rule 144(i) under the Securities Act. The financial statements of the
Company included in the SEC Reports comply in all material respects with applicable
accounting requirements and the rules and regulations of the Commission with respect thereto
as in effect at the time of filing or as amended or corrected in a subsequent SEC Report.
Such financial statements have been prepared in accordance with United States generally
accepted accounting principles applied on a consistent basis during the periods involved
(“GAAP”), except as may be otherwise specified in such financial statements or the
notes thereto and except that unaudited financial statements may not contain all footnotes
required by GAAP, and fairly present in all material respects the financial position of the
Company and its consolidated Subsidiaries as of and for the dates thereof and the results of
operations and cash flows for the periods then ended, subject, in the case of unaudited
statements, to normal, immaterial, year-end audit adjustments.

     (i) Material Changes; Undisclosed Events, Liabilities or Developments. Since
the date of the latest audited financial statements included within the SEC Reports, except
as specifically disclosed in a subsequent SEC Report filed prior to the date hereof: (i)
there has been no event, occurrence or development that has had or that could reasonably be
expected to result in a Material Adverse Effect, (ii) the Company has not incurred any
liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses
incurred in the ordinary course of business consistent with past practice and (B)
liabilities not required to be reflected in the Company’s financial statements pursuant to
GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its
method of accounting, (iv) except in connection with the conversion of the Company’s 5%
Series B Convertible Preferred Stock, 5% Series C Convertible Preferred Stock and 4.25660%
Series D Convertible Preferred Stock, the Company has not declared or made any dividend or
distribution of cash or other property to its stockholders or purchased, redeemed or made
any agreements to purchase or redeem any shares of its capital stock and (v) the Company has
not issued any equity securities to any officer, director or Affiliate, except pursuant to
existing Company equity incentive plans. The Company does not have pending before the
Commission any request for confidential treatment of information. Except for the issuance
of the Securities contemplated by this Agreement, the issuance of a warrant to Rodman &
Renshaw, LLC as compensation for its services as placement agent, and as set forth on
Schedule 3.1(i), no event, liability, fact, circumstance, occurrence or development
has occurred or exists or is reasonably expected to occur or exist with respect to the
Company or its Subsidiaries or their respective business, properties, operations, assets or
financial condition, that would be required to be disclosed by the Company under applicable
securities laws at the time this representation is made or deemed made that has not been
publicly disclosed at least 1 Trading Day prior to the date that this representation is
made.

     (j) Litigation. There is no action, suit, inquiry, notice of violation,
proceeding or investigation pending or, to the knowledge of the Company, threatened against
or affecting the Company, any Subsidiary or any of their respective properties before or by
any court, arbitrator, governmental or administrative agency or regulatory authority

11

 

(federal, state, county, local or foreign) (collectively, an “Action”) which
(i) adversely affects or challenges the legality, validity or enforceability of any of the
Transaction Documents or the Securities or (ii) could, if there were an unfavorable
decision, reasonably be expected to result in a Material Adverse Effect. Neither the
Company nor any Subsidiary, nor, to the knowledge of the Company, any director or officer
thereof, is or has been the subject of any Action involving a claim of violation of or
liability under federal or state securities laws or a claim of breach of fiduciary duty.
There has not been, and to the knowledge of the Company, there is not pending or
contemplated, any investigation by the Commission involving the Company or any current or
former director or officer of the Company. The Commission has not issued any stop order or
other order suspending the effectiveness of any registration statement filed by the Company
or any Subsidiary under the Exchange Act or the Securities Act.

     (k) Labor Relations. No material labor dispute exists or, to the knowledge of
the Company, is imminent with respect to any of the employees of the Company, which could
reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its
Subsidiaries’ employees is a member of a union that relates to such employee’s relationship
with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is
a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. No executive officer, to the
knowledge of the Company, is, or is now expected to be, in violation of any material term of
any employment contract, confidentiality, disclosure or proprietary information agreement or
non-competition agreement, or any other contract or agreement or any restrictive covenant in
favor of any third party, and the continued employment of each such executive officer does
not subject the Company or any of its Subsidiaries to any liability with respect to any of
the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S.
federal, state, local and foreign laws and regulations relating to employment and employment
practices, terms and conditions of employment and wages and hours, except where the failure
to be in compliance could not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect.

     (l) Compliance. Neither the Company nor any Subsidiary: (i) is in default
under or in violation of (and no event has occurred that has not been waived that, with
notice or lapse of time or both, would result in a default by the Company or any Subsidiary
under), nor has the Company or any Subsidiary received notice of a claim that it is in
default under or that it is in violation of, any indenture, loan or credit agreement or any
other agreement or instrument to which it is a party or by which it or any of its properties
is bound (whether or not such default or violation has been waived), (ii) is in violation of
any judgment, decree or order of any court, arbitrator or governmental body or (iii) is or
has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating
to taxes, environmental protection, occupational health and safety, product quality and
safety and employment and labor matters, except in each case as could not reasonably be
expected to result in a Material Adverse Effect.

     (m) Regulatory Permits. The Company and the Subsidiaries possess all
certificates, authorizations and permits issued by the appropriate federal, state, local or
foreign regulatory authorities necessary to conduct their respective businesses as described
in the SEC Reports, except where the failure to possess such permits could not

12

 

reasonably be expected to result in a Material Adverse Effect (“Material
Permits”), and neither the Company nor any Subsidiary has received any notice of
proceedings relating to the revocation or modification of any Material Permit. For clarity,
the Company has not received the approval of any regulatory agency to market or sell any of
its product candidates.

     (n) Title to Assets. The Company and the Subsidiaries have good and marketable
title in fee simple to all real property owned by them and good and marketable title in all
personal property owned by them that is material to the business of the Company and the
Subsidiaries, in each case free and clear of all Liens, except for Liens as do not
materially affect the value of such property and do not materially interfere with the use
made and proposed to be made of such property by the Company and the Subsidiaries and Liens
for the payment of federal, state or other taxes, the payment of which is neither delinquent
nor subject to penalties. Any real property and facilities held under lease by the Company
and the Subsidiaries are held by them under valid, subsisting and enforceable leases with
which the Company and the Subsidiaries are in compliance, except where such non-compliance
would not reasonably be expected to have a Material Adverse Effect.

     (o) Patents and Trademarks. The Company and the Subsidiaries have, or have
rights to use, all patents, patent applications, trademarks, trademark applications, service
marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual
property rights and similar rights as described in the SEC Reports as necessary or material
for use in connection with their respective businesses and which the failure to have could
reasonably be expected to have a Material Adverse Effect (collectively, the
“Intellectual Property Rights”). Neither the Company nor any Subsidiary has
received, since the date of the latest audited financial statements included within the SEC
Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual
Property Rights violate or infringe upon the rights of any Person, except as would not have
a Material Adverse Effect. To the knowledge of the Company, all such Intellectual Property
Rights are enforceable and there is no existing infringement by another Person of any of the
Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable
security measures to protect the secrecy, confidentiality and value of all of their
intellectual properties, except where failure to do so could not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect.

     (p) Insurance. The Company and the Subsidiaries are insured by insurers of
recognized financial responsibility against such losses and risks and in such amounts as are
prudent and customary for companies of similar size as the Company in the businesses in
which the Company and the Subsidiaries are engaged, including, but not limited to, directors
and officers insurance coverage at least equal to the aggregate Subscription Amount.
Neither the Company nor any Subsidiary has any reason to believe that it will not be able to
renew its existing insurance coverage as and when such coverage expires or to obtain similar
coverage from similar insurers as may be necessary to continue its business without a
significant increase in cost.

     (q) Transactions With Affiliates and Employees. Except as set forth in the SEC
Reports, none of the officers or directors of the Company and, to the knowledge of the
Company, none of the employees of the Company is presently a party to any transaction with
the Company or any Subsidiary (other than for services as employees,

13

 

officers and directors), including any contract, agreement or other arrangement
providing for the furnishing of services to or by, providing for rental of real or personal
property to or from, or otherwise requiring payments to or from any officer, director or
such employee or, to the knowledge of the Company, any entity in which any officer,
director, or any such employee has a substantial interest or is an officer, director,
trustee or partner, in each case in excess of $120,000 other than for: (i) payment of salary
or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf
of the Company and (iii) other employee benefits, including stock option or other equity
award agreements under any equity incentive plan of the Company.

     (r) Sarbanes-Oxley; Internal Accounting Controls. The Company is in compliance
with any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are
effective as of the date hereof, and any and all applicable rules and regulations
promulgated by the Commission thereunder that are effective as of the date hereof and as of
the Closing Date. The Company and the Subsidiaries maintain a system of internal accounting
controls sufficient to provide reasonable assurance that: (i) transactions are executed in
accordance with management’s general or specific authorizations, (ii) transactions are
recorded as necessary to permit preparation of financial statements in conformity with GAAP
and to maintain asset accountability, (iii) access to assets is permitted only in accordance
with management’s general or specific authorization, and (iv) the recorded accountability
for assets is compared with the existing assets at reasonable intervals and appropriate
action is taken with respect to any differences. The Company has established disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the
Company designed to ensure that information required to be disclosed by the Company in the
reports it files or submits under the Exchange Act is recorded, processed, summarized and
reported, within the time periods specified in the Commission’s rules and forms. The
Company’s certifying officers have evaluated the effectiveness of the Company’s disclosure
controls and procedures as of the end of the period covered by the Company’s most recently
filed periodic report under the Exchange Act (such date, the “Evaluation Date”). The
Company presented in its most recently filed periodic report under the Exchange Act the
conclusions of the certifying officers about the effectiveness of the disclosure controls
and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation
Date, there have been no changes in the Company’s internal control over financial reporting
(as such term is defined in the Exchange Act) that has materially and adversely affected, or
is reasonably likely to materially and adversely affect, the Company’s internal control over
financial reporting.

     (s) Certain Fees. Except as set forth in the Prospectus Supplement, no
brokerage or finder’s fees or commissions are or will be payable by the Company to any
broker, financial advisor or consultant, finder, placement agent, investment banker, bank or
other Person with respect to the transactions contemplated by the Transaction Documents.
The Purchasers shall have no obligation with respect to any fees or with respect to any
claims made by or on behalf of other Persons for fees of a type contemplated in this Section
that may be due in connection with the transactions contemplated by the Transaction
Documents.

     (t) Investment Company. The Company is not, and is not an Affiliate of, and
immediately after receipt of payment for the Securities, will not be or be an Affiliate of,
an “investment company” within the meaning of the Investment Company Act of 1940,

14

 

as amended. The Company currently intends to conduct its business in a manner so that
it will not become an “investment company” subject to registration under the Investment
Company Act of 1940, as amended.

     (u) Registration Rights. No Person has any right to cause the Company to
effect the registration under the Securities Act of any securities of the Company.

     (v) Listing and Maintenance Requirements. The Common Stock is registered
pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action
designed to, or which to its knowledge is likely to have the effect of, terminating the
registration of the Common Stock under the Exchange Act nor has the Company received any
notification that the Commission is contemplating terminating such registration. The
Company has not, in the 12 months preceding the date hereof, received notice from any
Trading Market on which the Common Stock is or has been listed or quoted to the effect that
the Company is not in compliance with the listing or maintenance requirements of such
Trading Market.

     (w) Application of Takeover Protections. The Company and the Board of
Directors have taken all necessary action, if any, in order to render inapplicable any
control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or other similar anti-takeover provision under the Company’s
certificate of incorporation (or similar charter documents) or the laws of its state of
incorporation that is or could become applicable to the Purchasers as a result of the
Purchasers and the Company fulfilling their obligations or exercising their rights under the
Transaction Documents, including without limitation as a result of the Company’s issuance of
the Securities and the Purchasers’ ownership of the Securities.

     (x) Disclosure. Except with respect to the material terms and conditions of
the transactions contemplated by the Transaction Documents, the Company confirms that
neither it nor any other Person acting on its behalf has provided any of the Purchasers or
their agents or counsel with any information that it believes constitutes or might
constitute material, non-public information which is not otherwise disclosed in the
Prospectus Supplement. The Company understands and confirms that the Purchasers will rely
on the foregoing representation in effecting transactions in securities of the Company. All
of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the
Company, its business and the transactions contemplated hereby, including the Disclosure
Schedules to this Agreement, is true and correct in all material respects and does not
contain any untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements made therein, in light of the circumstances under which they
were made, not misleading. The press releases disseminated by the Company during the
twelve months preceding the date of this Agreement taken as a whole do not contain any
untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made and when made, not misleading. The Company acknowledges and
agrees that no Purchaser makes or has made any representations or warranties with respect to
the transactions contemplated hereby other than those specifically set forth in Section 3.2
hereof.

     (y) No Integrated Offering. Assuming the accuracy of the Purchasers’
representations and warranties set forth in Section 3.2, neither the Company, nor any of

15

 

its Affiliates, nor any Person acting on its or their behalf has, directly or
indirectly, made any offers or sales of any security or solicited any offers to buy any
security, under circumstances that would cause this offering of the Securities to be
integrated with prior offerings by the Company for purposes of any applicable shareholder
approval provisions of any Trading Market on which any of the securities of the Company are
listed or designated.

     (z) Solvency. Based on the consolidated financial condition of the Company as
of the Closing Date, after giving effect to the receipt by the Company of the proceeds from
the sale of the Securities hereunder: (i) the fair saleable value of the Company’s assets
exceeds the amount that will be required to be paid on or in respect of the Company’s
existing debts and other liabilities (including known contingent liabilities) as they
mature, and (ii) the current cash flow of the Company, together with the proceeds the
Company would receive, were it to liquidate all of its assets, after taking into account all
anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its
liabilities when such amounts are required to be paid. The Company has no knowledge of any
facts or circumstances which lead it to believe that it will file for reorganization or
liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year
from the Closing Date. Schedule 3.1(z) sets forth as of the date hereof all
outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for
which the Company or any Subsidiary has commitments. For the purposes of this Agreement,
“Indebtedness” means (x) any liabilities for borrowed money or amounts owed in
excess of $50,000 (other than accrued liabilities and trade accounts payable incurred in the
ordinary course of business), (y) all guaranties, endorsements and other contingent
obligations in respect of indebtedness of others, whether or not the same are or should be
reflected in the Company’s balance sheet (or the notes thereto), except guaranties by
endorsement of negotiable instruments for deposit or collection or similar transactions in
the ordinary course of business; and (z) the present value of any lease payments in excess
of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither the
Company nor any Subsidiary is in default with respect to any Indebtedness.

     (aa) Tax Status. Except for matters that would not, individually or in the
aggregate, have or reasonably be expected to result in a Material Adverse Effect, the
Company and each Subsidiary (i) has made or filed all United States federal and state income
and all foreign income and franchise tax returns, reports and declarations required by any
jurisdiction to which it is subject, (ii) has paid all taxes and other governmental
assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations and (iii) has set aside on its books provision reasonably
adequate for the payment of all material taxes for periods subsequent to the periods to
which such returns, reports or declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any jurisdiction, and the officers of
the Company or of any Subsidiary know of no basis for any such claim.

     (bb) Foreign Corrupt Practices. Neither the Company, nor to the knowledge of
the Company, any agent or other person acting on behalf of the Company, has: (i) directly or
indirectly, used any funds for unlawful contributions, gifts, entertainment or other
unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or
domestic political parties or campaigns from corporate funds, (iii) failed to

16

 

disclose fully any contribution made by the Company (or made by any person acting on
its behalf of which the Company is aware) which is in violation of law or (iv) violated in
any material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended.

     (cc) Accountants. The Company’s accounting firm is J.H. Cohn LLP. To the
knowledge and belief of the Company, such accounting firm: (i) is a registered public
accounting firm as required by the Exchange Act and (ii) shall express its opinion with
respect to the financial statements to be included in the Company’s Annual Report on Form
10-K for the year ending December 31, 2009, which opinion may include a “going concern”
qualification.

     (dd) Acknowledgment Regarding Purchasers’ Purchase of Securities. The Company
acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an
arm’s length purchaser with respect to the Transaction Documents and the transactions
contemplated thereby. The Company further acknowledges that no Purchaser is acting as a
financial advisor or fiduciary of the Company (or in any similar capacity) with respect to
the Transaction Documents and the transactions contemplated thereby and any advice given by
any Purchaser or any of their respective representatives or agents in connection with the
Transaction Documents and the transactions contemplated thereby is merely incidental to the
Purchasers’ purchase of the Securities. The Company further represents to each Purchaser
that the Company’s decision to enter into this Agreement and the other Transaction Documents
has been based solely on the independent evaluation of the transactions contemplated hereby
by the Company and its representatives.

     (ee) Acknowledgment Regarding Purchaser’s Trading Activity. Anything in this
Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(f)
and 4.14 hereof), it is understood and acknowledged by the Company that: (i) none of the
Purchasers have been asked by the Company to agree, nor has any Purchaser agreed, to desist
from purchasing or selling, long and/or short, securities of the Company, or “derivative”
securities based on securities issued by the Company or to hold the Securities for any
specified term, (ii) past or future open market or other transactions by any Purchaser,
specifically including, without limitation, Short Sales or “derivative” transactions, before
or after the closing of this or future private placement transactions, may negatively impact
the market price of the Company’s publicly-traded securities, (iii) any Purchaser, and
counter-parties in “derivative” transactions to which any such Purchaser is a party,
directly or indirectly, may presently have a “short” position in the Common Stock and (iv)
each Purchaser shall not be deemed to have any affiliation with or control over any arm’s
length counter-party in any “derivative” transaction. The Company further understands and
acknowledges that (y) one or more Purchasers may engage in hedging activities at various
times during the period that the Securities are outstanding, including, without limitation,
during the periods that the value of the Underlying Shares deliverable with respect to
Securities are being determined, and (z) such hedging activities (if any) could reduce the
value of the existing stockholders’ equity interests in the Company at and after the time
that the hedging activities are being conducted. The Company acknowledges that such
aforementioned hedging activities do not constitute a breach of any of the Transaction
Documents.

     (ff) Regulation M Compliance. The Company has not, and to its knowledge no

17

 

one acting on its behalf has, (i) taken, directly or indirectly, any action designed to
cause or to result in the stabilization or manipulation of the price of any security of the
Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for,
purchased, or paid any compensation for soliciting purchases of, any of the Securities, or
(iii) paid or agreed to pay to any Person any compensation for soliciting another to
purchase any other securities of the Company, other than, in the case of clauses (ii) and
(iii), compensation paid to the Company’s placement agent in connection with the placement
of the Securities.

     (gg) FDA. As to each product subject to the jurisdiction of the U.S. Food and
Drug Administration (“FDA”) under the Federal Food, Drug and Cosmetic Act, as
amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged,
labeled, tested, distributed, sold, and/or marketed by the Company or any of its
Subsidiaries (each such product, a “Pharmaceutical Product”), such Pharmaceutical
Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed
by the Company in compliance with all applicable requirements under FDCA and similar laws,
rules and regulations relating to registration, investigational use, premarket clearance,
licensure, or application approval, good manufacturing practices, good laboratory practices,
good clinical practices, product listing, quotas, labeling, advertising, record keeping and
filing of reports, except where the failure to be in compliance would not have a Material
Adverse Effect. There is no pending, completed or, to the Company’s knowledge, threatened,
action (including any lawsuit, arbitration, or legal or administrative or regulatory
proceeding, charge, complaint, or investigation) against the Company or any of its
Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice,
warning letter or other communication from the FDA or any other governmental entity, which
(i) contests the premarket clearance, licensure, registration, or approval of, the uses of,
the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the
labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of,
requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of
advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii)
imposes a clinical hold on any clinical investigation by the Company or any of its
Subsidiaries, (iv) enjoins production at any facility of the Company or any of its
Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction
with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any
laws, rules or regulations by the Company or any of its Subsidiaries, and which, either
individually or in the aggregate, would have a Material Adverse Effect. The properties,
business and operations of the Company have been and are being conducted in all material
respects in accordance with all applicable laws, rules and regulations of the FDA. The
Company has not been informed by the FDA that the FDA will prohibit the marketing, sale,
license or use in the United States of any product proposed to be developed, produced or
marketed by the Company nor has the FDA expressed any concern as to approving or clearing
for marketing any product being developed or proposed to be developed by the Company. For
clarity, the Company has not received the approval of any regulatory agency to market or
sell any of its product candidates.

     (hh) Stock Option Plans. To the knowledge of the Company, each stock option
granted by the Company under the Company’s equity incentive plan was granted (i) in
accordance with the terms of the Company’s stock option plan and (ii) with an exercise price
at least equal to the fair market value of the Common Stock on the date such stock

18

 

option would be considered granted under GAAP and applicable law. To the knowledge of
the Company, no stock option granted under the Company’s stock option plan has been
backdated. The Company has not knowingly granted, and there is no and has been no Company
policy or practice to knowingly grant, stock options prior to, or otherwise knowingly
coordinate the grant of stock options with, the release or other public announcement of
material information regarding the Company or its Subsidiaries or their financial results or
prospects.

     (ii) Office of Foreign Assets Control. Neither the Company nor, to the
Company’s knowledge, any director, officer, agent, employee or affiliate of the Company is
currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control
of the U.S. Treasury Department (“OFAC”).

     (jj) U.S. Real Property Holding Corporation. The Company is not and has never
been a U.S. real property holding corporation within the meaning of Section 897 of the
Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser’s
request.

     (kk) Bank Holding Company Act. Neither the Company nor any of its Subsidiaries
or Affiliates is subject to the Bank Holding Company Act of 1956, as amended (the
“BHCA”) and to regulation by the Board of Governors of the Federal Reserve System
(the “Federal Reserve”). Neither the Company nor any of its Subsidiaries or
Affiliates owns or controls, directly or indirectly, five percent (5%) or more of the
outstanding shares of any class of voting securities or twenty-five percent or more of the
total equity of a bank or any entity that is subject to the BHCA and to regulation by the
Federal Reserve. Neither the Company nor any of its Subsidiaries or Affiliates exercises a
controlling influence over the management or policies of a bank or any entity that is
subject to the BHCA and to regulation by the Federal Reserve.

     (ll) Money Laundering. The operations of the Company are and have been
conducted at all times in compliance with applicable financial record-keeping and reporting
requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
applicable money laundering statutes and applicable rules and regulations thereunder
(collectively, the “Money Laundering Laws”), and no action, suit or proceeding by or
before any court or governmental agency, authority or body or any arbitrator involving the
Company with respect to the Money Laundering Laws is pending or, to the knowledge of the
Company, threatened.

     3.2 Representations and Warranties of the Purchasers. Each Purchaser, for itself and
for no other Purchaser, hereby represents and warrants as of the date hereof and as of the Closing
Date to the Company as follows (unless as of a specific date therein):

     (a) Organization; Authority. Such Purchaser is either an individual or an
entity duly organized, validly existing and in good standing under the laws of the
jurisdiction of its organization with full right, corporate or partnership power and
authority to enter into and to consummate the transactions contemplated by the Transaction
Documents and otherwise to carry out its obligations hereunder and thereunder. The execution
and delivery of the Transaction Documents and performance by such Purchaser of the
transactions contemplated by the Transaction Documents have been duly authorized by all
necessary corporate, partnership, limited liability company or

19

 

similar action, as applicable, on the part of such Purchaser. Each Transaction
Document to which it is a party has been duly executed by such Purchaser, and when delivered
by such Purchaser in accordance with the terms hereof, will constitute the valid and legally
binding obligation of such Purchaser, enforceable against it in accordance with its terms,
except: (i) as limited by general equitable principles and applicable bankruptcy,
insolvency, reorganization, moratorium and other laws of general application affecting
enforcement of creditors’ rights generally, (ii) as limited by laws relating to the
availability of specific performance, injunctive relief or other equitable remedies and
(iii) insofar as indemnification and contribution provisions may be limited by applicable
law.

     (b) No Conflicts. The execution, delivery and performance by such Purchaser of
this Agreement and the consummation by such Purchaser of the transactions contemplated hereby
do not and will not (i) conflict with or violate any provision of such Purchaser’s
certificate or articles of incorporation, bylaws, or other organizational or charter
documents, or (ii) conflict with or result in a violation of any law, rule, regulation,
order, judgment, injunction, decree or other restriction of any court or governmental
authority to which such Purchaser is subject (including federal and state securities laws and
regulations), or by which any property or asset of such Purchaser is bound or affected.

     (c) Understanding or Arrangement. [INTENTIONALLY OMITTED]

     (d) Purchaser Status. At the time such Purchaser was offered the Securities,
it was, and as of the date hereof it is, and on the Closing Date and on each date on which
it exercises any Warrants for cash it will be either: (i)
an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8)
under the Securities Act or (ii) a “qualified institutional buyer” as defined in Rule
144A(a) under the Securities Act. Such Purchaser is not required to be registered as a
broker-dealer under Section 15 of the Exchange Act.

     (e) Experience of Such Purchaser. Such Purchaser acknowledges and understands
that (i) its investment in the Securities involves a high degree of risk and (ii) nothing in
the Transaction Documents or SEC Reports constitutes legal, tax or investment advice. Such
Purchaser, either alone or together with its representatives, has such knowledge,
sophistication and experience in business and financial matters so as to be capable of
evaluating the merits and risks of the prospective investment in the Securities, and has so
evaluated the merits and risks of such investment. Such Purchaser is able to bear the
economic risk of an investment in the Securities and, at the present time, is able to afford
a complete loss of such investment.

     (f) Certain Transactions and Confidentiality. Other than consummating the
transactions contemplated hereunder, such Purchaser has not directly or indirectly, nor has
any Person acting on behalf of or pursuant to any understanding with such Purchaser,
executed any purchases or sales, including Short Sales, of the securities of the Company

20

 

during the period commencing as of the time that such Purchaser first received
information (written or oral) from the Company or any other Person representing the Company
setting forth the proposed terms of the transactions contemplated hereunder and ending
immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a
Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers
manage separate portions of such Purchaser’s assets and the portfolio managers have no
direct knowledge of the investment decisions made by the portfolio managers managing other
portions of such Purchaser’s assets, the representation set forth above shall only apply
with respect to the portion of assets managed by the portfolio manager that made the
investment decision to purchase the Securities covered by this Agreement. Other than to
other Persons party to this Agreement, such Purchaser has maintained the confidentiality of
all disclosures made to it in connection with this transaction (including the existence and
terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing
contained herein shall constitute a representation or warranty, or preclude any actions,
with respect to the identification of the availability of, or securing of, available shares
to borrow in order to effect Short Sales or similar transactions in the future.

The Company acknowledges and agrees that the representations contained in Section 3.2 shall not
modify, amend or affect such Purchaser’s right to rely on the Company’s representations and
warranties contained in this Agreement or any representations and warranties contained in any other
Transaction Document or any other document or instrument executed and/or delivered in connection
with this Agreement or the consummation of the transaction contemplated hereby.

ARTICLE IV.

OTHER AGREEMENTS OF THE PARTIES

     4.1 Underlying Shares. The shares of Common Stock underlying the shares of Preferred
Stock shall be issued free of legends. If all or any portion of a Warrant is exercised at a time
when there is an effective registration statement to cover the issuance or resale of the Warrant
Shares or if the Warrant is exercised via cashless exercise more than six months after the date of
issuance of the Warrant (or one year in the event there is not adequate current public information
available with respect to the Company as required by subsection (c) of Rule 144) and the holder is
not and has not been an Affiliate of the Company within the 90 days prior to the date of exercise
of the Warrant, the Warrant Shares issued pursuant to any such exercise shall be issued free of all
legends. If at any time following the date hereof the Registration Statement (or any subsequent
registration statement registering the sale or resale of the Warrant Shares) is not effective or is
not otherwise available for the sale or resale of the Warrant Shares, the Company shall immediately
notify the holders of the Warrants in writing that such registration statement is not then
effective and thereafter shall promptly notify such holders when the registration statement is
effective again and available for the sale or resale of the Warrant Shares (it being understood and
agreed that the foregoing shall not limit the ability of the Company to issue, or any Purchaser to
sell, any of the Warrant Shares in compliance with applicable federal and state securities laws).
The Company shall use reasonable best efforts to keep a registration statement (including the
Registration Statement) registering the issuance or resale of the Warrant Shares effective until
the earliest of (i) the time that the Warrants have expired, and (ii) the six-month anniversary of
the date of issuance of the Warrants (or the one-year anniversary of the date of issuance in the
event there is not adequate current public information available with respect to the Company as
required by subsection (c) of Rule 144).

21

 

     4.2 Acknowledgment of Dilution. The Company acknowledges that the issuance of the
Securities may result in dilution of the outstanding shares of Common Stock, which dilution may be
substantial under certain market conditions. The Company further acknowledges that its obligations
under the Transaction Documents, including, without limitation, its obligation to issue the
Underlying Shares pursuant to the Transaction Documents, are unconditional and absolute and not
subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of any
such dilution or any claim the Company may have against any Purchaser and regardless of the
dilutive effect that such issuance may have on the ownership of the other stockholders of the
Company.

     4.3 Furnishing of Information; Public Information. Until the earliest of the time
that (i) no Purchaser owns Securities or (ii) one year from the Closing Date, the Company covenants
to use its reasonable best efforts to maintain the registration of the Common Stock under Section
12(b) or 12(g) of the Exchange Act and to timely file (or obtain extensions in respect thereof and
file within the applicable grace period) all reports required to be filed by the Company after the
date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting
requirements of the Exchange Act. As long as any Purchaser owns Securities, if the Company is
not required to file reports pursuant to the Exchange Act, it will prepare and furnish to the
Purchasers and make publicly available in accordance with Rule 144(c) such information as is
required for the Purchasers to sell the Securities under Rule 144. The Company further covenants
that it will take such further action as any holder of Securities may reasonably request, to the
extent required from time to time to enable such Person to sell such Securities without
registration under the Securities Act within the requirements of the exemption provided by Rule
144.

     4.4 Integration. The Company shall not sell, offer for sale or solicit offers to buy
or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act)
that would be integrated with the offer or sale of the Securities for purposes of the rules and
regulations of any Trading Market such that it would require shareholder approval prior to the
closing of such other transaction unless shareholder approval is obtained before the closing of
such subsequent transaction.

     4.5 Conversion and Exercise Procedures. Each of the form of Notice of Exercise
included in the Warrants and the form of Notice of Conversion included in the Certificate of
Designation set forth the totality of the procedures required of the Purchasers in order to
exercise the Warrants or convert the Preferred Stock. No additional legal opinion, other
information or instructions shall be required of the Purchasers to exercise their Warrants or
convert their Preferred Stock. The Company shall honor exercises of the Warrants and conversions
of the Preferred Stock and shall deliver Underlying Shares in accordance with the terms, conditions
and time periods set forth in the Transaction Documents.

     4.6
Securities Laws Disclosure; Publicity. The Company shall, (a) by 9:30 a.m. (New York
City time) on the date hereof, issue a press release disclosing the material terms of the
transactions contemplated hereby and (b) by the end of the first Trading Day immediately following the
date hereof shall file a Current Report on Form 8-K, and including the Transaction Documents as
exhibits thereto. From and after the issuance of such press release, the Company shall have publicly disclosed all material, non-public information delivered to
any of the Purchasers by the Company or any of its subsidiaries, or any of their respective
officers, directors, employees or agents in connection with the transactions contemplated by the
Transaction Documents. The Company and each Purchaser shall consult

22

 

with each other in issuing any other press releases with respect to the transactions
contemplated hereby (other than with respect to the closing of the transaction contemplated by the
Transaction Documents), and neither the Company nor any Purchaser shall issue any such press
release nor otherwise make any such public statement without the prior consent of the Company, with
respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with
respect to any press release of the Company, which consent shall not unreasonably be withheld or
delayed, except if such disclosure is required by law, in which case the disclosing party shall
promptly provide the other party with prior notice of such public statement or communication.
Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser,
or include the name of any Purchaser in any filing with the Commission or any regulatory agency or
Trading Market, without the prior written consent of such Purchaser, except: (a) as required by
federal securities law in connection with the filing of final Transaction Documents (including
signature pages thereto) with the Commission and (b) to the extent such disclosure is required by
law or Trading Market regulations, in which case the Company shall provide the Purchasers with
prior notice of such disclosure permitted under this clause (b).

     4.7 Shareholder Rights Plan. No claim will be made or enforced by the Company or,
with the consent of the Company, any other Person, that any Purchaser is an “Acquiring
Person” under any control share acquisition, business combination, poison pill (including any
distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or
hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions
of any such plan or arrangement, solely by virtue of receiving Securities under the Transaction
Documents or under any other agreement between the Company and the Purchasers.

     4.8 Non-Public Information. Except with respect to the material terms and conditions
of the transactions contemplated by the Transaction Documents, the Company covenants and agrees
that neither it, nor any other Person acting on its behalf, will provide any Purchaser or its
agents or counsel with any information that the Company believes constitutes material non-public
information, unless prior thereto such Purchaser shall have executed a written agreement with the
Company regarding the confidentiality and use of such information. The Company understands and
confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions
in securities of the Company.

     4.9 Use of Proceeds. Except as set forth in the Prospectus Supplement, the Company
shall use the net proceeds from the sale of the Securities hereunder for working capital purposes
and shall not use such proceeds for: (a) the satisfaction of any portion of the Company’s debt
(other than payment of trade payables in the ordinary course of the Company’s business and prior
practices), (b) the redemption of any Common Stock or Common Stock Equivalents or (c) the
settlement of any outstanding litigation, and shall not use such proceeds in violation of the FCPA
or OFAC regulations.

     4.10 Indemnification of Purchasers. Subject to the provisions of this Section 4.10
and to the extent permitted by law, the Company will indemnify and hold each Purchaser and its
directors, officers, shareholders, members, partners, employees and agents (and any other Persons
with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such
title or any other title), each Person who controls such Purchaser (within the meaning of Section
15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers,
shareholders, agents, members, partners or employees (and any other Persons with a functionally
equivalent role of a Person holding such titles notwithstanding a lack of such title or any other
title) of such controlling persons (each, a “Purchaser Party”) harmless from any and all losses,

23

 

liabilities, obligations, claims, contingencies, damages, costs and expenses, including all
judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of
investigation that any such Purchaser Party may suffer or incur as a result of or relating to (a)
any breach of any of the representations, warranties, covenants or agreements made by the Company
in this Agreement or in the other Transaction Documents or (b) any action instituted against a
Purchaser in any capacity, or any of them or their respective Affiliates, by any stockholder of the
Company who is not an Affiliate of such Purchaser, with respect to any of the transactions
contemplated by the Transaction Documents (unless such action is based upon a breach of such
Purchaser’s representations, warranties or covenants under the Transaction Documents or any
agreements or understandings such Purchaser may have with any such stockholder or any violations by
such Purchaser of state or federal securities laws or any conduct by such Purchaser which
constitutes fraud, gross negligence, willful misconduct or malfeasance (collectively, the
“Carve-Outs”)). If any action shall be brought against any Purchaser Party in respect of which
indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the
Company in writing, and the Company shall have the right to assume the defense thereof with counsel
of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have
the right to employ separate counsel in any such action and participate in the defense thereof, but
the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the
extent that (i) the employment thereof has been specifically authorized by the Company in writing,
(ii) the Company has failed after a reasonable period of time to assume such defense and to employ
counsel or (iii) in such action there is, in the reasonable opinion of counsel, a material conflict
on any material issue between the position of the Company and the position of such Purchaser Party,
in which case the Company shall be responsible for the reasonable fees and expenses of no more than
one such separate counsel. The Company will not be liable to any Purchaser Party under this
Agreement (y) for any settlement by a Purchaser Party effected without the Company’s prior written
consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the
extent that a loss, claim, damage or liability is attributable to any Purchaser Party’s breach of
any of the representations, warranties, covenants or agreements made by such Purchaser Party in
this Agreement or in the other Transaction Documents. The Company will have the exclusive right to
settle any claim or proceeding provided that the Company will not settle any such claim, action or
proceeding without the prior written consent of the Purchaser Party, which shall not be
unreasonably withheld or delayed; provided that such consent shall not be required if the
settlement includes a full and unconditional release of the Purchase Party from all liability
arising or that may arise out of such claim or proceeding and does not include a statement as to or
an admission or fault, culpability or a failure to act by or on behalf of any Purchaser Party. The
indemnification required by this Section 4.10 shall be made by periodic payments of the amount
thereof during the course of the investigation or defense, as and when bills are received or are
incurred. To the extent that any payment made to a Purchaser Party is determined to have been
improper by reason of the underlying action being based on conduct or circumstances set forth in
the definition of the Carve-Outs, such Purchase Party will promptly pay the Company such amount.
The indemnity agreements contained herein shall be in addition to any cause of action or similar
right
of any Purchaser Party against the Company or others and any liabilities the Company may be
subject to pursuant to law.

     4.11 Reservation and Listing of Securities.

     (a) The Company shall maintain a reserve from its duly authorized shares of Common
Stock for issuance pursuant to the Transaction Documents in such amount as may then be
required to fulfill its obligations in full under the Transaction Documents.

24

 

     (b) If, on any date, the number of authorized but unissued (and otherwise unreserved)
 shares of Common Stock is less than the Required Minimum on such date, then the Board of
Directors shall use commercially reasonable efforts to amend the Company’s certificate or
articles of incorporation to increase the number of authorized but unissued shares of Common
Stock to at least the Required Minimum at such time, as soon as possible and in any event
not later than the 75th day after such date.

     (c) The Company shall, if applicable: (i) in the time and manner required by the
principal Trading Market, prepare and file with such Trading Market an additional shares
listing application covering a number of shares of Common Stock at least equal to the
Required Minimum on the date of such application, (ii) take all steps necessary to cause
such shares of Common Stock to be approved for listing or quotation on such Trading Market
as soon as possible thereafter, (iii) provide to the Purchasers evidence of such listing or
quotation and (iv) use its reasonable best efforts to maintain the listing or quotation of
such Common Stock on any date at least equal to the Required Minimum on such date on such
Trading Market or another Trading Market.

     4.12 Subsequent Equity Sales.

     (a) From the date hereof until 90 days after the Closing Date, neither the Company nor
any Subsidiary shall issue, enter into any agreement to issue or announce the issuance or
proposed issuance of any shares of Common Stock or Common Stock Equivalents.

     (b) From the date hereof until such time as the earlier of one year after the Closing
Date or the date that no Purchaser holds any of the Securities, the Company shall be
prohibited from effecting or entering into an agreement to effect any issuance by the
Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents for cash
consideration (or a combination of units thereof) involving a Variable Rate Transaction.
“Variable Rate Transaction” means a transaction in which the Company (i) issues or
sells any debt or equity securities that are convertible into, exchangeable or exercisable
for, or include the right to receive, additional shares of Common Stock either (A) at a
conversion price, exercise price or exchange rate or other price that is based upon, and/or
varies with, the trading prices of or quotations for the shares of Common Stock at any time
after the initial issuance of such debt or equity securities or (B) with a conversion,
exercise or exchange price that is subject to being reset at some future date after the
initial issuance of such debt or equity security or upon the occurrence of specified or
contingent events directly or indirectly related to the business of the Company or the
market for the Common Stock or (ii) enters into any agreement, including, but not limited
to, an equity line of credit, whereby the Company may sell securities at a future determined
price. Any Purchaser shall be entitled to obtain injunctive relief against the Company to
preclude any such issuance, which remedy shall be in addition to any right to collect
damages.

     (c) Notwithstanding the foregoing, this Section 4.12 shall not apply in respect of an
Exempt Issuance, except that no Variable Rate Transaction shall be an Exempt Issuance.

     4.13 Equal Treatment of Purchasers. No consideration (including any modification of
any Transaction Document) shall be offered or paid to any Person to amend or consent to a

25

 

waiver or modification of any provision of any of the Transaction Documents unless the same
consideration is also offered to all of the parties to the Transaction Documents. For clarification
purposes, this provision constitutes a separate right granted to each Purchaser by the Company and
negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as
a class and shall not in any way be construed as the Purchasers acting in concert or as a group
with respect to the purchase, disposition or voting of Securities or otherwise.

     4.14 Certain Transactions and Confidentiality. Each Purchaser, severally and not
jointly with the other Purchasers, covenants that neither it, nor any Affiliate acting on its
behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales, of any of the Company’s securities during the period commencing with the execution of
this Agreement and ending at such time that the transactions contemplated by this Agreement are
first publicly announced pursuant to the initial press release as described in Section 4.6. Each
Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as
the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to
the initial press release as described in Section 4.6, such Purchaser will maintain the
confidentiality of the existence and terms of this transaction and the information included in the
Transaction Documents and the Disclosure Schedules. Notwithstanding the foregoing, and
notwithstanding anything contained in this Agreement to the contrary, the Company expressly
acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby
that it will not engage in effecting transactions in any securities of the Company after the time
that the transactions contemplated by this Agreement are first publicly announced pursuant to the
initial press release as described in Section 4.6, (ii) no Purchaser shall be restricted or
prohibited from effecting any transactions in any securities of the Company in accordance with
applicable securities laws from and after the time that the transactions contemplated by this
Agreement are first publicly announced pursuant to the initial press release as described in
Section 4.6 and (iii) no Purchaser shall have any duty of confidentiality to the Company or its
Subsidiaries after the issuance of the initial press release as described in Section 4.6.
Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment
vehicle whereby separate portfolio managers manage separate portions of such Purchaser’s assets and
the portfolio managers have no direct knowledge of the investment decisions made by the portfolio
managers managing other portions of such Purchaser’s assets, the covenant set forth above shall
only apply with respect to the portion of assets managed by the portfolio manager that made the
investment decision to purchase the Securities covered by this Agreement.

     4.15 Delivery of Certificates After Closing. The Company shall deliver, or cause to
be delivered, the respective Securities purchased by each Purchaser to such Purchaser within 3
Trading Days of the Closing Date.

ARTICLE V.

MISCELLANEOUS

     5.1 Termination. This Agreement may be terminated by any Purchaser, as to such
Purchaser’s obligations hereunder only and without any effect whatsoever on the obligations between
the Company and the other Purchasers, by written notice to the other parties, if the Closing has
not been consummated on or before January 7, 2010; provided, however, that such termination will
not affect the right of any party to sue for any breach by the other party (or parties).

26

 

     5.2 Fees and Expenses. Except as expressly set forth in the Transaction Documents to
the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and
other experts, if any, and all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement. The Company shall pay all
Transfer Agent fees, stamp taxes and other taxes and duties levied in connection with the delivery
of any Securities to the Purchasers.

     5.3 Entire Agreement. The Transaction Documents, together with the exhibits and
schedules thereto, the Prospectus and the Prospectus Supplement, contain the entire understanding
of the parties with respect to the subject matter hereof and supersede all prior agreements and
understandings, oral or written, with respect to such matters, which the parties acknowledge have
been merged into such documents, exhibits and schedules.

     5.4 Notices. Any and all notices or other communications or deliveries required or
permitted to be provided hereunder shall be in writing and shall be deemed given and effective on
the earliest of: (a) the date of transmission, if such notice or communication is delivered via
facsimile at the facsimile number set forth on the signature pages attached hereto prior to 5:30
p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of
transmission, if such notice or communication is delivered via facsimile at the facsimile number
set forth on the signature pages attached hereto on a day that is not a Trading Day or later than
5:30 p.m. (New York City time) on any Trading Day, (c) the second (2nd) Trading Day
following the date of mailing, if sent by U.S. nationally recognized overnight courier service or
(d) upon actual receipt by the party to whom such notice is required to be given. The address for
such notices and communications shall be as set forth on the signature pages attached hereto.

     5.5 Amendments; Waivers. No provision of this Agreement may be waived, modified,
supplemented or amended except in a written instrument signed, in the case of an amendment, by the
Company and the Purchasers holding at least 67% in interest of the Securities then outstanding or,
in the case of a waiver, by the party against whom enforcement of any such waived provision is
sought. No waiver of any default with respect to any provision, condition or requirement of this
Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent
default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or
omission of any party to exercise any right hereunder in any manner impair the exercise of any such
right.

     5.6 Headings. The headings herein are for convenience only, do not constitute a part
of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.

     5.7 Successors and Assigns. This Agreement shall be binding upon and inure to the
benefit of the parties and their successors and permitted assigns. The Company may not assign this
Agreement or any rights or obligations hereunder without the prior written consent of each
Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this
Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided that
such transferee agrees in writing to be bound, with respect to the transferred Securities, by the
provisions of the Transaction Documents that apply to the “Purchasers.”

     5.8 No Third-Party Beneficiaries. This Agreement is intended for the benefit of the
parties hereto and their respective successors and permitted assigns and is not for the benefit of,
nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in
Section 4.10.

27

 

     5.9 Governing Law. All questions concerning the construction, validity, enforcement
and interpretation of the Transaction Documents shall be governed by and construed and enforced in
accordance with the internal laws of the State of New York, without regard to the principles of
conflicts of law thereof. Each party agrees that all legal proceedings concerning the
interpretations, enforcement and defense of the transactions contemplated by this Agreement and any
other Transaction Documents (whether brought against a party hereto or its respective affiliates,
directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state
and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the
exclusive jurisdiction of the state and federal courts sitting in the City of New York, borough of
Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any
transaction contemplated hereby or discussed herein (including with respect to the enforcement of
any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any
such court, that such suit, action or proceeding is improper or is an inconvenient venue for such
proceeding. Each party hereby irrevocably waives personal service of process and consents to
process being served in any such suit, action or proceeding by mailing a copy thereof via
registered or certified mail or overnight delivery (with evidence of delivery) to such party at the
address in effect for notices to it under this Agreement and agrees that such service shall
constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by
law. If either party shall commence an action or proceeding to enforce any provisions of the
Transaction Documents, then, in addition to the obligations of the Company under Section 4.10, the
prevailing party in such action or proceeding shall be reimbursed by the other party for its
reasonable attorneys’ fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such action or proceeding.

     5.10 Survival. The representations and warranties contained herein shall survive the
Closing and the delivery of the Securities.

     5.11 Execution. This Agreement may be executed in two or more counterparts, all of
which when taken together shall be considered one and the same agreement and shall become effective
when counterparts have been signed by each party and delivered to the other party, it being
understood that both parties need not sign the same counterpart. In the event that any signature
is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such
signature shall create a valid and binding obligation of the party executing (or on whose behalf
such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature
page were an original thereof.

     5.12 Severability. If any term, provision, covenant or restriction of this Agreement
is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the
remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in
full force and effect and shall in no way be affected, impaired or invalidated, and the parties
hereto shall use their commercially reasonable efforts to find and employ an alternative means to
achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties
that they would have executed the remaining terms, provisions, covenants and restrictions without
including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

     5.13 Rescission and Withdrawal Right. Notwithstanding anything to the contrary
contained in (and without limiting any similar provisions of) any of the other Transaction

28

 

Documents, whenever any Purchaser exercises a right, election, demand or option under a
Transaction Document and the Company does not timely perform its related obligations within the
periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion from
time to time upon written notice to the Company, any relevant notice, demand or election in whole
or in part without prejudice to its future actions and rights; provided, however, that in the case
of a rescission of a conversion of the Preferred Stock or exercise of a Warrant, the applicable
Purchaser shall be required to return any shares of Common Stock subject to any such rescinded
conversion or exercise notice concurrently with the return to such Purchaser of the aggregate
exercise price paid to the Company for such shares and the restoration of such Purchaser’s right to
acquire such shares pursuant to such Purchaser’s Warrant (including, issuance of a replacement
warrant certificate evidencing such restored right).

     5.14 Replacement of Securities. If any certificate or instrument evidencing any
Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued
in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in
lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of
evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant
for a new certificate or instrument under such circumstances shall also pay any reasonable
third-party costs (including customary indemnity) associated with the issuance of such replacement
Securities.

     5.15 Remedies. In addition to being entitled to exercise all rights provided herein
or granted by law, including recovery of damages, each of the Purchasers and the Company will be
entitled to specific performance under the Transaction Documents. The parties agree that monetary
damages may not be adequate compensation for any loss incurred by reason of any breach of
obligations contained in the Transaction Documents and hereby agree to waive and not to assert in
any action for specific performance of any such obligation the defense that a remedy at law would
be adequate.

     5.16 Payment Set Aside. To the extent that the Company makes a payment or payments to
any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its rights
thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any
part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside,
recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the
Company, a trustee, receiver or any other person under any law (including, without limitation, any
bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent
of any such restoration the obligation or part thereof originally intended to be satisfied shall be
revived and continued in full force and effect as if such payment had not been made or such
enforcement or setoff had not occurred.

     5.17 Usury. To the extent it may lawfully do so, the Company hereby agrees not to
insist upon or plead or in any manner whatsoever claim, and will resist any and all efforts to be
compelled to take the benefit or advantage of, usury laws wherever enacted, now or at any time
hereafter in force, in connection with any claim, action or proceeding that may be brought by any
Purchaser in order to enforce any right or remedy under any Transaction Document. Notwithstanding
any provision to the contrary contained in any Transaction Document, it is expressly agreed and
provided that the total liability of the Company under the Transaction Documents for payments in
the nature of interest shall not exceed the maximum lawful rate authorized under applicable law
(the “Maximum Rate”), and, without limiting the foregoing, in no event shall any rate of
interest or default interest, or both of them, when aggregated with any

29

 

other sums in the nature of interest that the Company may be obligated to pay under the
Transaction Documents exceed such Maximum Rate. It is agreed that if the maximum contract rate of
interest allowed by law and applicable to the Transaction Documents is increased or decreased by
statute or any official governmental action subsequent to the date hereof, the new maximum contract
rate of interest allowed by law will be the Maximum Rate applicable to the Transaction Documents
from the Closing Date thereof forward, unless such application is precluded by applicable law. If
under any circumstances whatsoever, interest in excess of the Maximum Rate is paid by the Company
to any Purchaser with respect to indebtedness evidenced by the Transaction Documents, such excess
shall be applied by such Purchaser to the unpaid principal balance of any such indebtedness or be
refunded to the Company, the manner of handling such excess to be at such Purchaser’s election.

     5.18 Independent Nature of Purchasers’ Obligations and Rights. The obligations of
each Purchaser under any Transaction Document are several and not joint with the obligations of any
other Purchaser, and no Purchaser shall be responsible in any way for the performance or
non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing
contained herein or in any other Transaction Document, and no action taken by any Purchaser
pursuant thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a
joint venture or any other kind of entity, or create a presumption that the Purchasers are in any
way acting in concert or as a group with respect to such obligations or the transactions
contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights, including, without limitation, the rights arising out of this
Agreement or out of the other Transaction Documents, and it shall not be necessary for any other
Purchaser to be joined as an additional party in any proceeding for such purpose. Each Purchaser
has been represented by its own separate legal counsel in their review and negotiation of the
Transaction Documents. For reasons of administrative convenience only, each Purchaser and its
respective counsel have chosen to communicate with the Company through WS. WS does not represent
any of the Purchasers and only represents Rodman & Renshaw, LLC, the placement agent for the
transaction. The Company has elected to provide all Purchasers with the same terms and Transaction
Documents for the convenience of the Company and not because it was required or requested to do so
by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement
and in each other Transaction Document is between the Company and a Purchaser, solely, and not between
the Company and the Purchasers collectively and not between and among the Purchasers.

     5.19 Liquidated Damages. The Company’s obligations to pay any partial liquidated
damages or other amounts owing under the Transaction Documents is a continuing obligation of the
Company and shall not terminate until all unpaid partial liquidated damages and other amounts have
been paid notwithstanding the fact that the instrument or security pursuant to which such partial
liquidated damages or other amounts are due and payable shall have been canceled.

     5.20 Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking
of any action or the expiration of any right required or granted herein shall not be a Business
Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.

     5.21 Construction. The parties agree that each of them and/or their respective
counsel has reviewed and had an opportunity to revise the Transaction Documents and, therefore, the
normal rule of construction to the effect that any ambiguities are to be resolved against the
drafting party shall not be employed in the interpretation of the Transaction Documents or any
amendments hereto. In addition, each and every reference to share prices and shares of Common Stock
in any Transaction Document shall be subject to adjustment for reverse and forward stock

30

 

splits, stock dividends, stock combinations and other similar transactions of the Common Stock
that occur after the date of this Agreement.

     5.22 WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT
BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST
EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY
WAIVES FOREVER TRIAL BY JURY. 

(Signature Pages Follow)

31

 

     IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be
duly executed by their respective authorized signatories as of the date first indicated above.

	 	 	 	 	 	 	 
	ADVENTRX PHARMACEUTICALS, INC.	 	 	 	 
	 
	 	 	 	 	 	 
	By:
	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	Name: Brian M. Culley	 	 	 	 
	 	 	Title: Chief Business Officer and Senior Vice
President	 	 
	 
	 	 	 	 	 	 
	Address for Notice:	 	 	 	6725 Mesa Ridge Road, Suite 100
	 

	 	 	 	 	 	San Diego, CA 92121
	 

	 	 	 	 	 	Fax: (858) 552-0876
	 
	 	 	 	 	 	 
	With a copy to (which shall not constitute notice):	 	 	 	DLA Piper LLP (US)
	 

	 	 	 	 	 	4365 Executive Drive, Suite 1100
	 

	 	 	 	 	 	San Diego, CA 92121
	 

	 	 	 	 	 	Attention: Michael S. Kagnoff
	 

	 	 	 	 	 	Fax: (858) 677-1401

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE PAGES FOR PURCHASERS FOLLOW]

 

 

[PURCHASER SIGNATURE PAGE TO ANX SECURITIES PURCHASE AGREEMENT]

     IN WITNESS WHEREOF, the undersigned has caused this Securities Purchase Agreement to be duly
executed by its authorized signatory as of the date first indicated above.

	 	 	 
	Name of Purchaser:

	 	 
	 

	 	 

	 	 	 
	Signature of Authorized Signatory of Purchaser:

	 	 
	 

	 	 

	 	 	 
	Name of Authorized Signatory:
	 	 
	 

	 	 

	 	 	 
	Title of Authorized Signatory:

	 	 
	 

	 	 

	 	 	 
	Email Address of Authorized Signatory: 

	 	 
	 

	 	 

	 	 	 
	Facsimile Number of Authorized Signatory:

	 	 
	 

	 	 

Address for Notice of Purchaser:

Address for Delivery of Preferred Stock certificate and Warrants for Purchaser (if not same as
address for notice):

	 	 	 
	Subscription Amount:

	 	 
	 

	 	 

	 	 	 
	Shares of Preferred Stock:

	 	 
	 

	 	 

	 	 	 
	Warrant Shares:

	 	 
	 

	 	 

EIN Number: [PROVIDE THIS UNDER SEPARATE COVER]

 

 

Schedule 3.1(a)

	 	 	 
	Name of Subsidiary

	 	Jurisdiction of Organization
	 

	 	 
	SD Pharmaceuticals, Inc.

	 	Delaware
	 
	 	 
	ADVENRTRX (Europe) Ltd.

	 	United Kingdom

Schedule 3.1(z)

Under a retention and severance plan, if the employment of Mr. Culley or Mr. Keran, as applicable,
terminates at any time as a result of an involuntary termination, and such employee delivers and
does not revoke a general release of claims, which will also confirm any post-termination
obligations and/or restrictions applicable to such employee, such employee will be entitled to an
amount equal to twelve (12) months of such employee’s then-current base salary, less applicable
withholdings, and an amount equal to the estimated cost of continuing such employee’s health care
coverage and the coverage of such employee’s dependents who are covered at the time of the
involuntary termination under the Consolidated Omnibus Budget Reconciliation Act of 1985, as
amended, for a period equal to twelve (12) months. These severance benefits will be paid in a
lump-sum on the date the general release of claims becomes effective. The Company’s aggregate
contractual obligation under the retention and severance plan, including applicable payroll and
employer taxes, is approximately $650,000.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00167-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00167-of-00352.parquet"}]]